[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 80 of about 80
1. Huss WJ, Gray DR, Greenberg NM, Mohler JL, Smith GJ: Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Res; 2005 Aug 1;65(15):6640-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.
  • Putative prostate stem cells and prostate tumor stem cells in benign and malignant human prostate tissue, in primary human prostate xenografts, and in the transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model of prostate cancer, are defined by expression of breast cancer resistance protein (BCRP), a marker of pluripotent hematopoietic, muscle, and neural stem cells, and by an absence of androgen receptor (AR) protein.
  • In both benign and malignant human prostate tissue, the rare epithelial cells that express BCRP and lack AR protein are localized in the basal cell compartment, survive androgen deprivation, and maintain proliferative potential in the hypoxic, androgen-deprived prostate.
  • Putative prostate tumor stem cells that express BCRP but not AR protein in TRAMP are the source of a BCRP-negative and AR-negative, Foxa2- and SV40Tag-expressing, transit amplifying compartment that progresses to the poorly differentiated carcinomas that arise rapidly after castration.
  • Therefore, BCRP expression isolates prostate stem/tumor stem cells from the prostate tissue microenvironment through constitutive efflux of androgen, protecting the putative tumor stem cells from androgen deprivation, hypoxia, or adjuvant chemotherapy, and providing the nidus for recurrent prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NOVOBIOCIN .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061644.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA84296; United States / NCI NIH HHS / CA / P01 CA077739; United States / NCI NIH HHS / CA / CA77739; United States / NCI NIH HHS / CA / CA64851; United States / NIEHS NIH HHS / ES / ES07017; United States / NCI NIH HHS / CA / CA64865
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / Androgens; 0 / Indoles; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Receptors, Androgen; 17EC19951N / Novobiocin; CW5S8OP3VO / tryptoquivaline
  •  go-up   go-down


2. Abeysekara AM, Siriwardana HP, Abbas KF, Tanner P, Ojo AA: An unusually large myofibroblastoma in a male breast: a case report. J Med Case Rep; 2008;2:157

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusually large myofibroblastoma in a male breast: a case report.
  • INTRODUCTION: Myofibroblastoma of the breast is a rare benign stromal tumour seen predominantly in men.
  • We present a case of an unusually large myofibroblastoma, which mimicked a malignant breast tumour.
  • CASE PRESENTATION: A 65-year-old man presented with a rapid enlargement of the right breast over 6 weeks.
  • Examination revealed a firm 15 cm hemispherical lump occupying the whole of the right breast with peau d'orange appearance of the overlying skin and distortion of the nipple.
  • The clinical and radiological features suggested the possibility of sarcoma of the breast.
  • CONCLUSION: This unexpected presentation of an unusually large myofibroblastoma in a male breast is the largest reported to date.
  • Myofibroblastomas can mimic malignant neoplasms and the clinical significance of this entity lies primarily in its recognition as a distinctive benign neoplasm.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1022-9 [11474286.001]
  • [Cites] Am J Surg Pathol. 1994 Nov;18(11):1170-6 [7943539.001]
  • [Cites] Am J Surg Pathol. 1979 Dec;3(6):535-42 [534390.001]
  • [Cites] Am J Surg Pathol. 1987 Jul;11(7):493-502 [3037930.001]
  • (PMID = 18479528.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2396649
  •  go-up   go-down


3. Aloysius MM, Zaitoun AM, Bates TE, Ilyas M, Constantin-Teodosiu D, Rowlands BJ, Lobo DN: Immunohistochemical expression of mitochondrial membrane complexes (MMCs) I, III, IV and V in malignant and benign periampullary epithelium: a potential target for drug therapy of periampullary cancer? BMC Cancer; 2010;10:80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of mitochondrial membrane complexes (MMCs) I, III, IV and V in malignant and benign periampullary epithelium: a potential target for drug therapy of periampullary cancer?
  • RESULTS: MMCs I, III, IV and V were highly expressed (p < 0.05) in all primary periampullary cancers compared with metastatic lymph nodes and adjacent benign pancreas.
  • CONCLUSIONS: Differential expression of MMCs III, IV and V in primary periampullary cancers compared with adjacent benign periampullary tissue and chronic pancreatitis is a novel finding, which may render them attractive anticancer targets.
  • [MeSH-minor] Adult. Aged. Cell Proliferation. Epithelium / drug effects. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Oxidative Stress. Pancreas / pathology. Pancreatitis / pathology. Phosphorylation. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2000 Aug 18;289(5482):1150-1 [10970229.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jul;68(1):9-19 [11678313.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Nov 1;176(3):145-52 [11714246.001]
  • [Cites] Cell. 2003 Feb 21;112(4):481-90 [12600312.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2003 Jul;285(1):L189-98 [12665464.001]
  • [Cites] Trends Mol Med. 2004 Aug;10(8):372-8 [15310457.001]
  • [Cites] BMJ. 2004 Sep 18;329(7467):668-73 [15374918.001]
  • [Cites] Cancer. 1993 Dec 15;72(12):3641-7 [8252480.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1309-12 [9721092.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Mar 11;328(2):623-32 [15694394.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1606-25 [15887154.001]
  • [Cites] Biochem Pharmacol. 2005 Jul 1;70(1):1-12 [15907809.001]
  • [Cites] Cell Metab. 2005 Jun;1(6):401-8 [16054089.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):857-66 [16327764.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4787-97 [16892091.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4812-30 [16892093.001]
  • [Cites] Exp Physiol. 2006 Sep;91(5):807-19 [16857720.001]
  • [Cites] FEBS Lett. 2006 Oct 2;580(22):5125-9 [16979626.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Mar 2;354(1):50-5 [17214968.001]
  • [Cites] J Bioenerg Biomembr. 2007 Feb;39(1):65-72 [17294131.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Jul;293(1):C12-21 [17475665.001]
  • [Cites] Gut. 2007 Aug;56(8):1134-52 [17625148.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Dec 7;364(1):131-7 [17931597.001]
  • [Cites] Clin Cancer Res. 2009 Mar 1;15(5):1593-600 [19223492.001]
  • [Cites] BMC Cancer. 2009;9:327 [19754967.001]
  • [Cites] Oral Oncol. 2001 Jan;37(1):72-6 [11120486.001]
  • (PMID = 20202214.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2841142
  •  go-up   go-down


Advertisement
4. Li KL, Partridge SC, Joe BN, Gibbs JE, Lu Y, Esserman LJ, Hylton NM: Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging. Radiology; 2008 Jul;248(1):79-87
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging.
  • PURPOSE: To retrospectively evaluate high-spatial-resolution signal enhancement ratio (SER) imaging for the prediction of disease recurrence in patients with breast cancer who underwent preoperative magnetic resonance (MR) imaging.
  • From 1995 to 2002, gadolinium-enhanced MR imaging data were acquired with a three time point high-resolution method in women undergoing neoadjuvant therapy for invasive breast cancers.
  • RESULTS: Breast tumor volume calculated from the number of voxels with SER values above a threshold corresponding to the upper limit of mean redistribution rate constant in benign tumors (0.88 minutes(-1)) and the volume of cancerous breast tissue infiltrating into the parenchyma were important predictors of disease recurrence.
  • All three prechemotherapy parameters (total tumor volume, tumor volumes with high and low SER) and the postchemotherapy tumor volume with high SER were significantly different between the two groups.
  • The multivariate Cox proportional hazards regression showed that, of the three prechemotherapy covariates, only the low SER and high SER tumor volumes (P = .017 and .049, respectively) were significant and independent predictors of tumor recurrence.
  • Tumor volume with high SER was the only significant postchemotherapy covariate predictor (P = .038).
  • [MeSH-major] Breast Neoplasms / diagnosis. Image Enhancement / methods. Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2008.
  • [Cites] Med Phys. 1987 Jan-Feb;14(1):1-37 [3031439.001]
  • [Cites] J Magn Reson Imaging. 1997 Jan-Feb;7(1):91-101 [9039598.001]
  • [Cites] Radiology. 2005 Sep;236(3):789-800 [16118161.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):260-6 [10508285.001]
  • [Cites] Radiology. 1999 Apr;211(1):101-10 [10189459.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jun;184(6):1774-81 [15908529.001]
  • [Cites] Breast J. 1999 Jan;5(1):13-21 [11348250.001]
  • [Cites] Crit Rev Diagn Imaging. 1995;36(4):287-338 [8845065.001]
  • [Cites] Clin Radiol. 1997 Jul;52(7):516-26 [9240704.001]
  • [Cites] J Magn Reson Imaging. 2003 Oct;18(4):467-77 [14508784.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2001 May;9(2):321-32, vi [11493422.001]
  • [Cites] Magn Reson Med. 1995 Apr;33(4):564-8 [7776889.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):223-32 [10508281.001]
  • [Cites] Acta Radiol. 2003 Jul;44(4):373-8 [12846686.001]
  • [Cites] Radiology. 2006 May;239(2):361-74 [16543585.001]
  • [Cites] Cancer. 1996 May 1;77(9):1844-9 [8646683.001]
  • [Cites] Br J Radiol. 1998 May;71(845):501-9 [9691895.001]
  • [Cites] Breast Cancer Res Treat. 1997 Aug;45(1):39-46 [9285115.001]
  • [Cites] Magn Reson Med. 2007 Sep;58(3):572-81 [17685424.001]
  • [Cites] J Magn Reson Imaging. 2000 Dec;12(6):965-74 [11105038.001]
  • [Cites] Radiology. 1995 Oct;197(1):33-8 [7568850.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):708-18 [15971199.001]
  • [Cites] Acta Radiol. 1998 May;39(3):279-84 [9571944.001]
  • [Cites] Eur J Radiol. 2005 Feb;53(2):199-205 [15664283.001]
  • [Cites] Radiology. 1997 Dec;205(3):837-42 [9393545.001]
  • [Cites] J Magn Reson Imaging. 1999 Dec;10(6):945-9 [10581507.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):910-2 [11183740.001]
  • [Cites] J Comput Assist Tomogr. 2002 May-Jun;26(3):376-86 [12016367.001]
  • [Cites] J Comput Assist Tomogr. 1999 Jul-Aug;23(4):615-21 [10433296.001]
  • [Cites] Br J Radiol. 1997 May;70(833):446-51 [9227224.001]
  • [Cites] Eur Radiol. 2001;11(9):1645-50 [11511885.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):97-103 [8630946.001]
  • [Cites] J Magn Reson Imaging. 2005 Oct;22(4):511-9 [16161072.001]
  • [Cites] Magn Reson Imaging. 2004 May;22(4):475-81 [15120166.001]
  • (PMID = 18566170.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA069587; United States / NCI NIH HHS / CA / R01 CA116182
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Ismail MF, Aly MS, Khaled HM, Mohamed HM: Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer. Ger Med Sci; 2009;7:Doc03
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer.
  • Breast cancer is a leading cause of cancer-related deaths in women worldwide.
  • Amplification of the two oncogenes HER-2/neu and c-myc and inactivation of the tumor suppressor gene p53 are frequently encountered in breast carcinomas.
  • The study was conducted on 34 tissue samples obtained from 33 females and 1 male with breast carcinomas and 17 samples obtained from 16 females and 1 male with benign breast lesions.
  • Results revealed that the level of HER-2/neu, c-myc and p53 in the malignant group was significantly increased as compared to the benign group.
  • The sensitivity of the investigated markers significantly increased with larger tumor size.
  • Concerning tumor grade, HER-2/neu and p53 showed a significant increase in low-grade tumors whereas c-myc showed a highly significant increase in high-grade tumors.
  • [MeSH-major] Breast Neoplasms / genetics. In Situ Hybridization, Fluorescence / methods. Proto-Oncogene Proteins c-myc / analysis. Receptor, ErbB-2 / analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Biopsy. Breast Neoplasms, Male / diagnosis. Breast Neoplasms, Male / epidemiology. Breast Neoplasms, Male / genetics. Egypt / epidemiology. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Nucleic Acid Amplification Techniques / methods. Prevalence. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Jan;156(1):183-91 [10623666.001]
  • [Cites] Diagn Mol Pathol. 2007 Dec;16(4):207-10 [18043283.001]
  • [Cites] Breast Cancer Res Treat. 2000 Feb;59(3):211-21 [10832591.001]
  • [Cites] Indian J Exp Biol. 2000 Mar;38(3):225-30 [10927863.001]
  • [Cites] Ann Oncol. 2000 Jun;11(6):647-63 [10942052.001]
  • [Cites] Acta Oncol. 2000;39(3):327-33 [10987229.001]
  • [Cites] Endocr Relat Cancer. 2000 Sep;7(3):143-64 [11021963.001]
  • [Cites] Oncogene. 2000 Dec 11;19(53):6093-101 [11156522.001]
  • [Cites] Oncogene. 2000 Dec 11;19(53):6102-14 [11156523.001]
  • [Cites] Int J Cancer. 2001 Jul 20;95(4):266-70 [11400121.001]
  • [Cites] Tumour Biol. 2001 Sep-Oct;22(5):337-44 [11553865.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1481-8 [11888924.001]
  • [Cites] Breast Cancer Res Treat. 2002 Jul;74(1):25-31 [12150449.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):690-4 [12548612.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1612-9 [15083194.001]
  • [Cites] J Pathol. 2004 Aug;203(4):918-26 [15258994.001]
  • [Cites] Am J Clin Pathol. 2004 Aug;122(2):246-55 [15323142.001]
  • [Cites] Nature. 1986 Feb 27-Mar 5;319(6056):783-4 [3005871.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5321-5 [1351679.001]
  • [Cites] Nature. 1992 Jul 2;358(6381):15-6 [1614522.001]
  • [Cites] Cell Growth Differ. 1993 Jan;4(1):41-7 [8424905.001]
  • [Cites] Curr Opin Genet Dev. 1995 Feb;5(1):97-104 [7749333.001]
  • [Cites] J Pathol. 1995 Nov;177(3):225-32 [8551383.001]
  • [Cites] Oncogene. 1996 Jul 4;13(1):63-72 [8700555.001]
  • [Cites] Hum Pathol. 1998 Apr;29(4):323-9 [9563780.001]
  • [Cites] Breast Cancer Res Treat. 1998 May;49(1):35-9 [9694609.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1262-9 [9731732.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Oct;23(2):100-8 [9739012.001]
  • [Cites] Oncogene. 1999 May 13;18(19):3004-16 [10378696.001]
  • [Cites] Am J Clin Pathol. 1999 Oct;112(4):459-69 [10510669.001]
  • [Cites] Cancer. 2005 Mar 1;103(5):900-5 [15643600.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1909-17 [15753390.001]
  • [Cites] Oncol Rep. 2005 Apr;13(4):633-41 [15756435.001]
  • [Cites] Histopathology. 2005 Apr;46(4):431-41 [15810955.001]
  • [Cites] Rev Med Chir Soc Med Nat Iasi. 2004 Jul-Sep;108(3):657-61 [15832994.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):634-9 [16021569.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R598-604 [16168103.001]
  • [Cites] Indian J Pathol Microbiol. 2004 Jul;47(3):340-2 [16295419.001]
  • [Cites] Breast J. 2005 Nov-Dec;11(6):433-9 [16297088.001]
  • [Cites] Clin Exp Metastasis. 2005;22(6):495-502 [16320112.001]
  • [Cites] Breast Cancer Res. 2005;7(6):R1058-79 [16457687.001]
  • [Cites] J Clin Pathol. 2006 Apr;59(4):424-8 [16497871.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5330-7 [16707459.001]
  • [Cites] Oncologist. 2006 Sep;11(8):857-67 [16951389.001]
  • [Cites] Int J Oncol. 2006 Oct;29(4):973-80 [16964393.001]
  • [Cites] Int J Biol Markers. 2006 Jul-Sep;21(3):131-40 [17013794.001]
  • [Cites] Hua Xi Yi Ke Da Xue Xue Bao. 1998 Dec;29(4):399-401 [10743237.001]
  • (PMID = 19675743.001).
  • [ISSN] 1612-3174
  • [Journal-full-title] German medical science : GMS e-journal
  • [ISO-abbreviation] Ger Med Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2716551
  • [Keywords] NOTNLM ; HER-2/neu / breast cancer / c-myc / fluorescent in situ hybridization (FISH) / genetic alterations / p53
  •  go-up   go-down


6. Hiramatsu K, Takahashi K, Yamaguchi T, Matsumoto H, Miyamoto H, Tanaka S, Tanaka C, Tamamori Y, Imajo M, Kawaguchi M, Toi M, Mori T, Kawakita M: N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers. Clin Cancer Res; 2005 Apr 15;11(8):2986-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers.
  • PURPOSE: N(1),N(12)-diacetylspermine (DiAcSpm) in the urine of colorectal and breast cancer patients was examined to establish its usefulness as a novel diagnostic tool for detecting these cancers at clinically early stages.
  • EXPERIMENTAL DESIGN: Urine samples from 248 colon cancer patients and 83 breast cancer patients as well as 51 patients with benign gastrointestinal diseases treated in Tokyo Metropolitan Komagome Hospital during the period of August 1999 to January 2004 were collected.
  • DiAcSpm was elevated in 60% of tumor-node-metastasis cancer stage 0 + I patients, whereas only 10% (P < 0.0001) and 5% (P < 0.0001) of these patients were CEA- and CA19-9-positive, respectively.
  • The sensitivity of urinary DiAcSpm for 83 cases of breast cancer (60.2%) was higher than the sensitivities of CEA (37.3%, P = 0.0032) and CA15-3 (37.3%, P = 0.0032).
  • DiAcSpm was elevated in 28% of tumor-node-metastasis stage I + II patients, whereas only 3% (P = 0.0064) and 0% (P = 0.001) of these patients were CEA- and CA15-3-positive, respectively.
  • CONCLUSION: The observations indicate that urinary DiAcSpm is a more sensitive marker than CEA, CA19-9, and CA15-3 and that it can efficiently detect colorectal and breast cancers at early stages.
  • [MeSH-major] Biomarkers, Tumor. Breast Neoplasms / diagnosis. Colorectal Neoplasms / diagnosis. Spermine / analogs & derivatives
  • [MeSH-minor] Adult. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Mucin-1 / blood. Neoplasm Staging. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837752.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Mucin-1; 2FZ7Y3VOQX / Spermine; 77928-71-3 / N',N''-diacetylspermine
  •  go-up   go-down


7. Bianco C, Strizzi L, Mancino M, Rehman A, Hamada S, Watanabe K, De Luca A, Jones B, Balogh G, Russo J, Mailo D, Palaia R, D'Aiuto G, Botti G, Perrone F, Salomon DS, Normanno N: Identification of cripto-1 as a novel serologic marker for breast and colon cancer. Clin Cancer Res; 2006 Sep 1;12(17):5158-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of cripto-1 as a novel serologic marker for breast and colon cancer.
  • We evaluated whether CR-1 is present in the plasma of patients with breast and colon cancer, and if it can represent a new biomarker for these malignancies.
  • EXPERIMENTAL DESIGN: We determined CR-1 plasma levels using a sandwich-type ELISA in 21 healthy volunteers, 54 patients with breast cancer, 33 patients with colon carcinoma, and 21 patients with benign breast lesions.
  • A statistically significant increase in the levels of plasma CR-1 was found in patients with colon carcinoma (4.68+/-3.5 ng/mL) and in patients with breast carcinoma (2.97+/-1.48 ng/mL; P<0.001).
  • Although moderate levels of plasma CR-1 were found in women with benign lesions of the breast (1.7+/-0.99 ng/mL), these levels were significantly lower than in patients with breast cancer (P<0.001).
  • Finally, immunohistochemical analysis and real-time reverse transcription-PCR confirmed strong positivity for CR-1 in colon and/or breast tumor tissues.
  • CONCLUSION: This study suggests that plasma CR-1 might represent a novel biomarker for the detection of breast and colon carcinomas.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Colonic Neoplasms / blood. Colonic Neoplasms / diagnosis. Epidermal Growth Factor / blood. Membrane Glycoproteins / blood. Neoplasm Proteins / blood
  • [MeSH-minor] Animals. Enzyme-Linked Immunosorbent Assay / methods. Female. GPI-Linked Proteins. Humans. Immunohistochemistry / methods. Intercellular Signaling Peptides and Proteins. Male. Mice. Mice, Transgenic. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction / methods. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16951234.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / TDGF1 protein, human; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


8. Kondi-Pafitis A, Kairi-Vassilatou E, Grapsa D, Kalkounou I, Vassilikostas G, Psichogios I: A large benign vascular neoplasm of the male breast. A case report and review of the literature. Eur J Gynaecol Oncol; 2005;26(4):454-6
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A large benign vascular neoplasm of the male breast. A case report and review of the literature.
  • Breast hemangiomas are extremely rare neoplasms in the male population.
  • We report a case of a 77-year old man with a breast hemangioma which was detected in physical examination as a small nodule ten years after a chest injury.
  • The final histological diagnosis was hemangioma of the breast, 6 cm in the largest diameter.
  • To our knowledge, this is the largest benign vascular breast neoplasm in a male patient reported up to date.
  • The rarity of the lesion and its differential diagnosis from angiosarcoma are discussed while the problems encountered in the correct diagnosis and classification of this tumor are also presented.
  • The need for extreme caution in the interpretation of the histological characteristics of all palpable vascular tumors of the breast is emphasized.
  • [MeSH-major] Breast Neoplasms, Male / diagnosis. Hemangioma / diagnosis
  • [MeSH-minor] Aged. Humans. Male. Mastectomy, Segmental

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Gynaecol Oncol. 2005;26(6):667; author reply 667-8 [16398236.001]
  • (PMID = 16122203.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 10
  •  go-up   go-down


9. Papachristopoulou G, Avgeris M, Scorilas A: Expression analysis and study of KLK4 in benign and malignant breast tumours. Thromb Haemost; 2009 Feb;101(2):381-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression analysis and study of KLK4 in benign and malignant breast tumours.
  • The purpose of this study was the expression analysis and study of KLK4 in benign and malignant breast tumours.
  • Total RNA was isolated from 16 benign and 45 malignant breast tissue specimens.
  • Relative quantification analysis was performed using the comparative C(T) method 2(-DeltaDeltaC)(T) KLK4 expression was found to vary in both patients' cohorts; however, a statistically significant elevation of the KLK4 mRNA levels was observed in malignant compared to benign tumour patients.
  • ROC and logistic regression analysis recommended that KLK4 gene expression may be used as a new potential biomarker in breast cancer.
  • [MeSH-major] Biomarkers, Tumor / genetics. Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Kallikreins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Cell Line, Tumor. Female. Humans. Logistic Models. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Prognosis. RNA, Messenger / analysis. ROC Curve. Receptors, Progesterone / analysis. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190825.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Progesterone; EC 3.4.21.- / Kallikreins; EC 3.4.21.- / kallikrein 4
  •  go-up   go-down


10. Foschini MP, Krausz T: Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential. Semin Diagn Pathol; 2010 Feb;27(1):77-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential.
  • Salivary gland-type neoplasms of the breast are uncommon and comprise numerous entities analogous to that more commonly seen in salivary glands.
  • The clinicopathologic spectrum ranges from benign to malignant but there are important differences as compared with those of their salivary counterpart.
  • In the breast, benign adenomyoepithelioma is recognized in addition to malignant one, whereas in the salivary gland a histologically similar tumor is designated as epithelial-myoepithelial carcinoma without a separate benign subgroup.
  • Mammary adenoid cystic carcinoma is a low-grade neoplasm compared with its salivary equivalent.
  • It is also important to appreciate that in contrast to "triple negative" conventional breast carcinomas with aggressive course, most salivary-type malignant breast neoplasms behave in a low-grade manner.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Breast Neoplasms / pathology. Neoplasms, Complex and Mixed / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adenoma, Pleomorphic / metabolism. Adenoma, Pleomorphic / pathology. Adenomyoepithelioma / metabolism. Adenomyoepithelioma / pathology. Breast Neoplasms, Male / metabolism. Breast Neoplasms, Male / pathology. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Female. Humans. Male. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306833.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


11. Lauwers K, Bestman TJ, Bergmans G, Molderez C: Granular cell tumour of the male breast. Acta Chir Belg; 2008 Jan-Feb;108(1):112-4
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumour of the male breast.
  • Granular cell tumour (GCT) is a rare neoplasm that can be found in multiple sites throughout the body.
  • Occasionally GCT is located in the breast.
  • In general, it appears as a singular benign lesion, although it can be multi-focal and rare cases with malignant behaviour have been reported.
  • We report a rare case of granular cell tumour of the nipple in the male breast, treated by wide local excision.
  • [MeSH-major] Breast Neoplasms, Male / surgery. Granular Cell Tumor / surgery
  • [MeSH-minor] Aged. Humans. Immunohistochemistry. Male. Nipples

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18411585.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


12. Bacci G, Ferrari C, Longhi A, Ferrari S, Forni C, Bacchini P, Palmerini E, Briccoli A, Pignotti E, Balladelli A, Picci P: Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. J Pediatr Hematol Oncol; 2006 Dec;28(12):774-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy.
  • Twenty-six patients (2.15%) developed a second malignant neoplasm at a median of 7.6 years (1 to 25 y) after primary osteosarcoma treatment.
  • Second neoplasms were leukemia (10), breast (7), lung (2), kidney (2), central nervous system cancer (2), soft tissue (1), parotid (1), and colon (1).
  • The rate of second malignancies observed in the osteosarcoma group was significantly higher than that observed in the control group of 1160 patients with benign tumors treated in the same period at our Institute (2.2% vs. 0.8%, P<0.009).
  • Our study showed that the risk of second neoplasm within 15 years increased and then leveled off and that although secondary solid tumors could be explained as unrelated cases, leukemias seem to be over represented.
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant / methods. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Incidence. Infant. Male. Neoplasms / drug therapy. Neoplasms / epidemiology. Retrospective Studies. Risk Factors. Sex Factors. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164644.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Reid-Lombardo KM, Mathis KL, Wood CM, Harmsen WS, Sarr MG: Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management. Ann Surg; 2010 Jan;251(1):64-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management.
  • Two control groups consisting of Group 1-patients with a diagnosis of ductal pancreatic adenocarcinoma (1:1) and Group 2-a general referral population (3:1) were matched for gender and age at diagnosis, year of registration, and residence.
  • Logistic regression was used to assess the risk of a diagnosis of extrapancreatic neoplasms among cases versus controls.
  • The proportion of IPMN patients having any extrapancreatic neoplasm diagnosed before or coincident to the index date was 52% (95% CI, 47%-56%), compared with 36% (95% CI, 32%-41%) in Group 1 (P < 0.001), and 43% (95% CI, 41%-46%) in Group 2 (P = 0.002).
  • Benign neoplasms most frequent in the IPMN group were colonic polyps (n = 114) and Barrett's neoplasia (n = 18).
  • The most common malignant neoplasms were nonmelanoma skin (n = 35), breast (n = 24), prostate (n = 24), colorectal cancers (n = 19), and carcinoid neoplasms (n = 6).
  • [MeSH-major] Adenocarcinoma, Mucinous / therapy. Carcinoma, Pancreatic Ductal / therapy. Carcinoma, Papillary / therapy. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Aged. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19858708.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1 UL1 RR024150
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


14. Dakin Haché K, Gray S, Barnes PJ, Dewar R, Younis T, Rayson D: Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray. Breast Cancer Res Treat; 2007 Oct;105(2):169-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray.
  • BACKGROUND: Male breast cancer (MBC) commonly expresses hormone receptors and there is anecdotal evidence of disease responsivity to aromatase inhibitors in the metastatic setting.
  • Specimens were reviewed for standard pathologic characteristics and tumor blocks were incorporated into three TMA's (four 1 mm cores per tumor).
  • ITA staining intensity was compared to control, benign hepatic tissue and if greater than or equal to liver was scored positive and if less than liver was scored negative.
  • Median tumor size was 2.6 cm (0.3-8.0 cm) and 22(41%) had nodal metastases.
  • [MeSH-major] Aromatase / metabolism. Breast Neoplasms, Male / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Humans. Immunoenzyme Techniques. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Retrospective Studies. Survival Rate. Tissue Array Analysis


15. Madjar H, Becker S, Doubek K, Horchler T, Mendoza M, Moisidis-Tesch C, Näther B, Niebling K, Pröls U, Schardt AR, Ulrich S, Zahn U: [Impact of breast ultrasound screening in gynecological practice]. Ultraschall Med; 2010 Jun;31(3):289-95
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of breast ultrasound screening in gynecological practice].
  • [Transliterated title] Bedeutung der Mammasonografie für die Brustkrebsfrüherkennung in der gynäkologischen Praxis.
  • PURPOSE: To define the value of whole breast ultrasound for breast cancer detection in primary women's health care in gynecological routing practice.
  • MATERIALS AND METHODS: Among women who were operated at the breast center of the German Diagnostic Clinic (DKD) in the year 2007, we selected different indications for the examinations which were relevant for the detection of breast lesions.
  • RESULTS: Twenty-one of 86 breast cancers (24 %) which were treated at the DKD in the year 2007 were detected only because of an individual ultrasound screening examination.
  • In this group of patients, only 8 benign lesions detected by ultrasound were operated.
  • This corresponds to a ratio of benign vs. malignant operations of 0.4 to 1, which is far superior to the recommendations of international guidelines for quality assurance.
  • CONCLUSION: Our results show that ultrasound screening considerably increases the detection of early breast cancers without increasing the rate of unnecessary biopsies.
  • This should encourage gynecologists to learn and perform systematic breast ultrasound examinations and to increase their own performance by continuous training.
  • We can expect that additional studies will prove breast ultrasound to be a powerful method for improving breast cancer detection.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Carcinoma, Ductal, Breast / ultrasonography. Carcinoma, Intraductal, Noninfiltrating / ultrasonography. Carcinoma, Lobular / ultrasonography. Mass Screening. Ultrasonography, Mammary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Breast Diseases / pathology. Breast Diseases / surgery. Breast Diseases / ultrasonography. Early Diagnosis. Female. Germany. Humans. Male. Mammography. Middle Aged. Neoplasm Staging. Quality Assurance, Health Care. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Georg Thieme Verlag KG Stuttgart . New York.
  • (PMID = 20408119.001).
  • [ISSN] 1438-8782
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Youk JH, Kim EK, Kim MJ, Oh KK: Imaging findings of chest wall lesions on breast sonography. J Ultrasound Med; 2008 Jan;27(1):125-38
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging findings of chest wall lesions on breast sonography.
  • OBJECTIVE: The purpose of this presentation is to illustrate the sonographic findings of chest wall lesions that were depicted on breast sonography.
  • METHODS: Chest wall lesions detected during breast sonography were collected and reviewed retrospectively.
  • RESULTS: The sonographic findings of normal chest walls and various pathologic chest wall lesions, including inflammatory lesions, benign neoplasms, and malignant neoplasms, are discussed.
  • CONCLUSIONS: Familiarity with normal sonographic anatomy and chest wall lesions could be helpful in differentiating a chest wall lesion from a breast lesion and in showing whether the origin of any palpable breast lump is in the breast parenchyma or the chest wall on breast sonography.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Thoracic Wall / ultrasonography. Ultrasonography, Mammary
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis / ultrasonography. Neoplasm Recurrence, Local / ultrasonography. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18096738.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Li BJ, Huang XP, Wei WD, Wang JY, Su XD, Zhang X, Hong WS, Tang J, Zhang LJ, Long H, Yang MT, Rong TH: [Expression and clinical significance of cytokeratin 19 in bone marrow of patients with breast cancer]. Ai Zheng; 2005 Jun;24(6):735-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of cytokeratin 19 in bone marrow of patients with breast cancer].
  • BACKGROUND & OBJECTIVE: Breast cancer may undergo metastasis in early phase.
  • Distant metastasis, especially bone metastasis, may influence prognosis of breast cancer patients.
  • This study was designed to evaluate expression and clinical significance of cytokeratin 19 (CK19) in bone marrow of patients with breast cancer.
  • METHODS: Expression of CK19 mRNA in bone marrows of 65 breast cancer patients, 15 benign breast disease patients, and 8 healthy volunteers was detected by reverse transcription-polymerase chain reaction (RT-PCR).
  • Correlation of CK19 mRNA expression to clinicopathologic features of the 65 breast cancer patients was analyzed.
  • RESULTS: Positive rate of CK19 mRNA was 33.8% in the 65 breast cancer patients, and 0 in both benign breast disease patients and healthy volunteers.
  • Expression of CK19 mRNA was positively correlated with tumor size and clinical stage (P < 0.05), but was not related to age and lymph node status (P > 0.05).
  • CONCLUSIONS: CK19 mRNA may be used as a molecular marker to detect bone marrow micrometastasis in patients with breast cancer.
  • The detection may help to select proper therapy and predict prognosis of breast cancer patients.
  • [MeSH-major] Bone Marrow / metabolism. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Keratin-19 / biosynthesis
  • [MeSH-minor] Adult. Aged. Breast Neoplasms, Male / metabolism. Breast Neoplasms, Male / pathology. Carcinoembryonic Antigen / blood. Female. Fibroadenoma / blood. Fibroadenoma / metabolism. Fibroadenoma / pathology. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946491.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / RNA, Messenger
  •  go-up   go-down


18. Shukla R, Pooja B, Radhika S, Nijhawan R, Rajwanshi A: Fine-needle aspiration cytology of extramammary neoplasms metastatic to the breast. Diagn Cytopathol; 2005 Apr;32(4):193-7
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration cytology of extramammary neoplasms metastatic to the breast.
  • Fine-needle aspiration (FNA) biopsy is the first-line investigation in any breast lump and hence cytomorphological recognition of nonmammary metastatic tumors to the breast and their distinction from primary tumors is important.
  • Metastatic breast neoplasms diagnosed over a 6-yr period from 1997 to 2002 were retrieved from the database of the Department of Cytopathology and the clinical, cytopathological, histochemical, and immunohistochemical findings were correlated with the histopathology of the primary tumor.
  • Fifteen cases of metastatic breast neoplasms were encountered constituting 1.47% of all malignant tumors of the breast diagnosed on FNA.
  • There were 14 female patients and one male patient aged 13-80 yr.
  • The preaspiration clinical diagnosis was either a benign breast lump or a malignancy (primary vs. metastatic).
  • The breast lump was the initial presentation in four cases and the cytodiagnosis of a metastatic malignancy lead to the subsequent detection of the primary malignancy.
  • The presence of unusual cytomorphological patterns on breast FNA should alert the cytopathologist to the possibility of a metastatic breast neoplasm, even if not suspected clinically.
  • A detailed history of the patient, clinical correlation, and immunocytochemistry helps in establishing an accurate diagnosis, which avoids unnecessary surgery and ensures appropriate treatment.
  • [MeSH-major] Breast / pathology. Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / secondary
  • [MeSH-minor] Adolescent. Adult. Biopsy, Fine-Needle. Child. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / pathology. Predictive Value of Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15754368.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Wang F, Wang Z, Wu J, Qu W, Yao W, Zhao J, Liu Z: The role of technetium-99m-labeled octreotide acetate scintigraphy in suspected breast cancer and correlates with expression of SSTR. Nucl Med Biol; 2008 Aug;35(6):665-71
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of technetium-99m-labeled octreotide acetate scintigraphy in suspected breast cancer and correlates with expression of SSTR.
  • PURPOSE: To evaluate the value of (99m)Tc-octreotide acetate (hereafter, (99m)Tc-octreotide) somatostatin receptor (SSTR) scintigraphy in the detection of primary breast cancer and to correlate with expression of SSTRs.
  • MATERIALS AND METHODS: Fifty-four female and 1 male patients (range, 17-77 years; mean age, 48 years) with palpable breast lesion were included in this study. (99m)Tc-octreotide and (99m)Tc-MIBI scintigraphy were undertaken in all patients, and the region of interest was drawn around each lesion.
  • Tumor uptake was measured and expressed as the ratio of tumor to normal tissue activity (T/NT).
  • Final clinical diagnosis was confirmed by histopathological analysis.
  • Expression of SSTR1-5 mRNA was measured with RT-PCR in 15 patients with malignant neoplasm, and protein level of SSTR-2 and SSTR-5 was measured using immunohistochemical staining in 15 patients with malignant neoplasm and 18 patients with benign lesion.
  • RESULTS: Thirty-five patients were confirmed to have infiltrative ductal breast carcinoma, 1 patient with cellular cancer, 1 patient with adenocarcinoma and 18 patients had benign lesions.
  • CONCLUSION: (99m)Tc-octreotide acetate scintigraphy was sensitive for the detection of primary lesion of breast cancer; however, nonspecific breast tissue uptake hampered the specificity and clinical value in the detection of lymph node metastasis.
  • Five subtypes of SSTR mRNA and protein SSTR2 and SSTR5 were expressed variably in breast cancer due to tumor heterogeneity. (99m)Tc-octreotide imaging may hold promise in the evaluation of the level of SSTR2 in vivo.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / radionuclide imaging. Octreotide / analogs & derivatives. Organotechnetium Compounds / pharmacokinetics. Receptors, Somatostatin / metabolism
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Radiopharmaceuticals / pharmacokinetics. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18678351.001).
  • [ISSN] 0969-8051
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 99mTc-octreotide; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / Receptors, Somatostatin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


20. Shah SN: Giant myofibroblastoma of breast: a case report. Indian J Pathol Microbiol; 2007 Jul;50(3):583-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant myofibroblastoma of breast: a case report.
  • Myofibroblastoma of the breast is a very rare benign neoplasm usually seen in elderly male and is of very small size.
  • A 40 year old nulliparous woman was admitted with chief complain of massive enlargement of left breast.
  • The case was clinically diagnosed as Phyllodes tumor Left mastectomy was done.
  • The tumor was histopathologically and immunohistochemically diagnosed as Myofibroblastoma.
  • [MeSH-major] Breast Neoplasms / diagnosis. Neoplasms, Muscle Tissue / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883145.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


21. Majewska U, Banaś D, Braziewicz J, Góźdź S, Kubala-Kukuś A, Kucharzewski M: Trace element concentration distributions in breast, lung and colon tissues. Phys Med Biol; 2007 Jul 7;52(13):3895-911
Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trace element concentration distributions in breast, lung and colon tissues.
  • The concentrations of Fe, Cu, Zn and Se in cancerous and benign tissues of breast, lung and intestine (colon) have been determined.
  • Finally, the log-rank test has been applied to compare the elemental concentration distributions between cancerous and benign tissues of the same organ, between cancerous tissues and between benign tissues taken from different organs.
  • Comparing benign and malignant neoplastic tissues, statistically significant differences have been found between Fe and Se concentration distributions of breast as well as for Cu and Zn in the case of lung tissues and in the case of colon tissues for Zn.
  • The concentrations of all elements have been found to be statistically different in cancer tissues as well as in benign ones when comparing the different organs, i.e. groups 'breast-colon' and 'breast-lung'.
  • For benign tissues of lung and colon a statistically significant difference has been found only for Zn.
  • [MeSH-major] Breast / metabolism. Breast Neoplasms / metabolism. Colon / metabolism. Colonic Neoplasms / metabolism. Lung / metabolism. Lung Neoplasms / metabolism. Spectrometry, X-Ray Emission / methods. Trace Elements / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Iron / chemistry. Male. Middle Aged. Neoplasm Metastasis. Selenium / chemistry. Zinc / chemistry

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17664584.001).
  • [ISSN] 0031-9155
  • [Journal-full-title] Physics in medicine and biology
  • [ISO-abbreviation] Phys Med Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Trace Elements; E1UOL152H7 / Iron; H6241UJ22B / Selenium; J41CSQ7QDS / Zinc
  •  go-up   go-down


22. Roncella S, Ferro P, Franceschini MC, Bacigalupo B, Dessanti P, Sivori M, Carletti AM, Fontana V, Canessa PA, Pistillo MP, Fedeli F: Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin. Diagn Mol Pathol; 2010 Jun;19(2):92-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin.
  • As was reported that human mammaglobin (hMAM) may be expressed in malignant pleural effusions (PEs), we investigated the relevance of hMAM reverse-transcriptase polymerase chain reaction (RT-PCR) for their diagnosis and determination of primary origin.
  • Two hundred and twenty-eight malignant (132 male, 96 female) and 185 benign (132 male, 53 female) PEs were investigated.
  • Statistical analyses evaluated the diagnostic performance parameters in all PEs and in cytologically negative malignant PEs, the association between hMAM and benign or malignant status by the direct index of correlation [diagnostic odds ratio (DOR)], chi test, and P value (P).
  • In addition, the discriminative diagnostic power of hMAM expression, independently in breast cancer, lung cancer (LC), malignant mesothelioma (MM), and other cancers was evaluated.
  • In the entire patient population, hMAM was detected in 45.6% and 5.4% of malignant and benign PEs, respectively, in the male group in 41.7% and 4.5% and in the female group in 51.0% and 7.5% of malignant and benign PEs, respectively.
  • A statistically significant correlation between hMAM and malignancy was found in the entire population (DOR=14.68, P<0.001) and in the male (DOR=15.00, P<0.001) or female (DOR=12.77, P<0.001) groups. hMAM RT-PCR increased the diagnostic rate of malignant PEs as it allowed us to detect as malignant 32.1% of cytologically negative PEs.
  • In female patients the positivity of hMAM indicated with higher probability (50.8%) the origin of PEs from breast cancer but lower probability from LC (17%), MM (9.4%), or other cancers (15.1%), whereas in male patients it indicated with similar probability (about 40%) the origin from LC or MM.
  • Our results suggest that hMAM RT-PCR may provide information both in the diagnosis of PE and in the search for the primary site of neoplasia, either in male or female patients.
  • [MeSH-major] Breast Neoplasms / complications. Breast Neoplasms / diagnosis. Neoplasm Proteins / genetics. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / etiology. Reverse Transcriptase Polymerase Chain Reaction / methods. Uteroglobin / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Female. Humans. Male. Mammaglobin A. Middle Aged. United States. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20502186.001).
  • [ISSN] 1533-4066
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


23. Papantoniou V, Tsiouris S, Koutsikos J, Sotiropoulou M, Mainta E, Lazaris D, Valsamaki P, Melissinou M, Zerva C, Antsaklis A: Scintimammographic detection of usual ductal breast hyperplasia with increased proliferation rate at risk for malignancy. Nucl Med Commun; 2006 Nov;27(11):911-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scintimammographic detection of usual ductal breast hyperplasia with increased proliferation rate at risk for malignancy.
  • OBJECTIVES: To estimate whether breast uptake of (99m)Tc-(V)DMSA and (99m)Tc-sestamibi in usual ductal epithelial breast hyperplasia (UDH) and apocrine metaplasia is related to cell proliferation rate (Ki-67) and oestrogen receptor (ER) expression, both of which are associated with the potential risk of evolving to malignancy.
  • METHODS: Among patients referred for suspicious breast findings on palpation and/or mammography and evaluated preoperatively with both radiopharmaceuticals, we retrospectively studied 17 (10 with UDH: group I; and seven with apocrine metaplasia: group II).
  • This could prove useful in identifying women with benign but high-risk breast pathologies who might benefit from chemoprophylaxis.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Hyperplasia / radionuclide imaging. Ki-67 Antigen / analysis. Precancerous Conditions / radionuclide imaging. Receptors, Estrogen / analysis. Risk Assessment / methods. Technetium Tc 99m Sestamibi
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cell Proliferation. Humans. Male. Middle Aged. Neoplasm Invasiveness. Radiopharmaceuticals / pharmacokinetics. Retrospective Studies. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17021432.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Radiopharmaceuticals; 0 / Receptors, Estrogen; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


24. Li BJ, Wang JY, Wang HY, Huang XP, Zhang LJ, Long H, Yang MT, Rong TH: [Clinical significance of hMAM mRNA detection in bone marrow of breast carcinoma patient]. Zhonghua Zhong Liu Za Zhi; 2006 Oct;28(10):766-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of hMAM mRNA detection in bone marrow of breast carcinoma patient].
  • OBJECTIVE: To investigate the expression of the human mammoglobin (hMAM) mRNA in bone marrow and its clinical significance in the breast cancer patient.
  • METHODS: Expression of hMAM mRNA was detected using nested reverse transcription polymerase chain reaction (RT-PCR) in the bone marrow aspiration sample from 75 breast cancer patients, 15 patients with benign breast lesions and 8 healthy volunteers as control.
  • The hMAM mRNA was found to be positively expressed by RT-PCR in 21 of 75 breast cancer patients with a positive rate of 28.0%.
  • However, hMAM mRNA expression was not detected in the bone marrow aspiration samples from patients with benign breast lesions and healthy volunteers.
  • The hMAM mRNA expression was positively correlated with axillary nodal involvement and progesterone receptor (PR) status (P < 0.05) as well as Ki67 expression in breast cancer tissue (chi2 = 4.936, P = 0.026), but not with age, tumor size, clinical stage, or estrogen receptor (ER) status (P > 0.05).
  • CONCLUSION: RT-PCR is quite sensitive and has a high specificity in detecting the presence of hMAM mRNA in the bone marrow from breast cancer patients.
  • Thereupon, hMAM mRNA may be useful as a molecular biomarker in detecting disseminated tumor cells (DTC) in the bone marrow of breast cancer patients.
  • [MeSH-major] Bone Marrow / metabolism. Breast Neoplasms / genetics. Breast Neoplasms, Male / genetics. Neoplasm Proteins / genetics. Uteroglobin / genetics
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / genetics. Breast / metabolism. Breast / pathology. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / pathology. Female. Fibroadenoma / genetics. Fibroadenoma / pathology. Humans. Ki-67 Antigen / genetics. Lymphatic Metastasis. Male. Mammaglobin A. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptors, Progesterone / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17366790.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Receptors, Progesterone; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


25. Chung A, Schoder H, Sampson M, Morrow M, Port E: Incidental breast lesions identified by 18F-fluorodeoxyglucose-positron emission tomography. Ann Surg Oncol; 2010 Aug;17(8):2119-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental breast lesions identified by 18F-fluorodeoxyglucose-positron emission tomography.
  • We describe our experience with breast incidentalomas in a large series of PET scans performed for patients without a known history of breast cancer.
  • MATERIALS AND METHODS: From March 2000 through June 2007, approximately 45,000 PET scans were performed; 163 had breast findings unrelated to the primary malignancy.
  • In 103 of 163 (63%), findings included physiologic variation, lactation, implants, or benign calcifications.
  • Additional breast imaging was performed in 14 of 40 (35%).
  • CONCLUSIONS: In our experience, 29% of breast incidentalomas (7 of 24) with persistent imaging findings were malignant.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Incidental Findings. Positron-Emission Tomography / methods. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / radionuclide imaging. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20162459.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


26. de Lyra EC, da Silva IA, Katayama ML, Brentani MM, Nonogaki S, Góes JC, Folgueira MA: 25(OH)D3 and 1,25(OH)2D3 serum concentration and breast tissue expression of 1alpha-hydroxylase, 24-hydroxylase and Vitamin D receptor in women with and without breast cancer. J Steroid Biochem Mol Biol; 2006 Aug;100(4-5):184-92
Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 25(OH)D3 and 1,25(OH)2D3 serum concentration and breast tissue expression of 1alpha-hydroxylase, 24-hydroxylase and Vitamin D receptor in women with and without breast cancer.
  • 1,25(OH)2D3 is an antiproliferative agent that may inhibit proliferation of breast cancer (BC) cells in vitro and BC development in animals.
  • To unravel the role of Vitamin D3 in BC patients, we have investigated serum levels of 25(OH)D3 and its active form 1,25(OH)2D3 as well as tissue expression of 1alpha-hydroxylase, 24-hydroxylase, and Vitamin D-receptor (VDR), determined by semiquantitative RT-PCR, in 88 Brazilian BC patients and 35 women without cancer (submitted to mammoplasties or resection of benign lesions).
  • Our results indicate that 24-hydroxylase, VDR and 1alpha-hydroxylase mRNA tissue expression is similar in both groups and no correlation between 24-hydroxylase, 1alpha-hydroxylase, and VDR expression in breast tumors was found.
  • A low 1,25(OH)2D3 serum concentration seems to be associated to breast cancer, however, the mechanism involved in this regulation is still unclear.
  • [MeSH-major] 25-Hydroxyvitamin D3 1-alpha-Hydroxylase / metabolism. Breast / metabolism. Breast Neoplasms / metabolism. Calcifediol / blood. Calcitriol / blood. Receptors, Calcitriol / metabolism. Steroid Hydroxylases / metabolism
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / metabolism. Brazil. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Regression Analysis. Vitamin D3 24-Hydroxylase

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16828283.001).
  • [ISSN] 0960-0760
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Calcitriol; EC 1.14.- / 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; EC 1.14.- / Steroid Hydroxylases; EC 1.14.13.126 / Vitamin D3 24-Hydroxylase; FXC9231JVH / Calcitriol; P6YZ13C99Q / Calcifediol
  •  go-up   go-down


27. Sampatanukul P, Boonjunwetwat D, Thanakit V, Pak-Art P: Integrated criteria of fine-needle aspiration cytology and radiological imaging for verification of breast cancer in nonpalpable lesions. J Med Assoc Thai; 2006 Feb;89(2):236-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrated criteria of fine-needle aspiration cytology and radiological imaging for verification of breast cancer in nonpalpable lesions.
  • OBJECTIVES: To evaluate the accuracy of using radiologic, cytologic and integrated radiologic and cytologic criteria in diagnosis of nonpalpable breast lesions.
  • RESULTS: There were 162 lesions from 150 patients, consisting of 29 malignant neoplasms (17.9%) and 133 benign lesions (82.1%).
  • Two others had falsely negative cytologic diagnosis.
  • CONCLUSION: The integrated criteria provide the most accuracy rate and sensitivity rate for detection of malignancy in nonpalpable breast lesions.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / radiography. Carcinoma / pathology. Carcinoma / radiography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Cohort Studies. Female. Humans. Immunohistochemistry. Male. Mammography / methods. Middle Aged. Neoplasm Staging. Prospective Studies. Risk Assessment. Sensitivity and Specificity. Survival Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16579012.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  •  go-up   go-down


28. Duncan VE, Reddy VV, Jhala NC, Chhieng DC, Jhala DN: Non-Hodgkin's lymphoma of the breast: a review of 18 primary and secondary cases. Ann Diagn Pathol; 2006 Jun;10(3):144-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma of the breast: a review of 18 primary and secondary cases.
  • We evaluated the clinical features, morphology, and incidence of 18 cases of breast lymphoma over 10 years at the University of Alabama at Birmingham.
  • Fine needle aspiration was consistent with the tissue diagnosis in 6 of the 7 cases (86%).
  • One case was diagnosed by fine needle aspiration as atypical cells, favor benign; the biopsy revealed diffuse large B-cell lymphoma.
  • The remaining 4 cases (22%) were plasma cell neoplasm, T-cell neoplasm, Burkitt's lymphoma, and precursor B-cell lymphoblastic lymphoma.
  • Flow cytometry and/or gene rearrangement supported the diagnosis of lymphoma in 8 cases.
  • Although rare, lymphoma should be considered in the differential diagnosis of a breast mass.
  • [MeSH-major] Breast Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Female. Gene Rearrangement. Humans. Immunophenotyping. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16730308.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Yilmaz MH, Ozguroglu M, Mert D, Turna H, Demir G, Adaletli I, Ulus S, Halac M, Kanberoğlu K: Diagnostic value of magnetic resonance imaging and scintigraphy in patients with metastatic breast cancer of the axial skeleton: a comparative study. Med Oncol; 2008;25(3):257-63
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of magnetic resonance imaging and scintigraphy in patients with metastatic breast cancer of the axial skeleton: a comparative study.
  • PATIENTS AND METHODS: A total of 59 patients (58 women and 1 man, age range 28-83 years, mean age 53.0 years) with histopathologically proven breast cancer during a 15-month period (between April 2003 and January 2004) were included in the study.
  • Four lesions detected by MRI were classified as of uncertain origin (grade 2) and 36 lesions were regarded as definitely benign (grade 1).
  • A total of 29 lesions were considered as of uncertain origin (grade 2), and 26 lesions were regarded as definitely benign (grade 1).
  • About five lesions were graded as grade 2 in scintigraphy, while MRI graded them as degeneration or benign compression (Grade 1).
  • [MeSH-major] Bone Neoplasms / secondary. Breast Neoplasms / pathology. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diphosphonates. Female. Humans. Male. Middle Aged. Neoplasm Staging. Organotechnetium Compounds. Predictive Value of Tests. Sensitivity and Specificity. Whole Body Imaging

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18040900.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Organotechnetium Compounds; 0 / technetium 99m methylene bisphosphonate
  •  go-up   go-down


30. Ribeiro-Silva A, Mendes CF, Costa IS, de Moura HB, Tiezzi DG, Andrade JM: Metastases to the breast from extramammary malignancies: a clinicopathologic study of 12 cases. Pol J Pathol; 2006;57(3):161-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastases to the breast from extramammary malignancies: a clinicopathologic study of 12 cases.
  • Along with a brief review of the literature, we report the clinicopathologic features of 12 cases of extramammary malignancies metastatic to the breast.
  • Histological diagnoses of the primary tumor were as follows: non-Hodgkin diffuse large B-cell lymphoma (3 patients), acute mycloid leukemia (3 patients), serous papillary adenocarcinoma, well-differentiated adenocarcinoma, squamous cell carcinoma, undifferentiated neoplasm, mesothelioma, and melanoma.
  • The interval between diagnosis of primary cancer and the appearance of breast metastasis ranged from 0 to 108 months (mean: 17, median: 1).
  • Survival after the detection of the breast metastases ranged from 0.2 to 144 months (mean: 23, median: 9.5).
  • In conclusion, metastasis can mimic either benign disease or primary malignancy and is often an unexpected diagnosis in a patient presenting with a breast mass.
  • Thus, an accurate diagnosis is important to avoid unnecessary mutilating surgery.
  • [MeSH-major] Breast Neoplasms / secondary. Neoplasm Metastasis
  • [MeSH-minor] Adolescent. Adult. Aged. Breast Neoplasms, Male / radiography. Breast Neoplasms, Male / secondary. Child. Female. Humans. Male. Mammography. Middle Aged. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17219743.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


31. Mainiero MB, Cinelli CM, Koelliker SL, Graves TA, Chung MA: Axillary ultrasound and fine-needle aspiration in the preoperative evaluation of the breast cancer patient: an algorithm based on tumor size and lymph node appearance. AJR Am J Roentgenol; 2010 Nov;195(5):1261-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Axillary ultrasound and fine-needle aspiration in the preoperative evaluation of the breast cancer patient: an algorithm based on tumor size and lymph node appearance.
  • OBJECTIVE: The objective of our study was to evaluate the utility of ultrasound-guided fine-needle aspiration (FNA) of the axillary lymph nodes in breast cancer patients depending on the size of the primary tumor and the appearance of the lymph nodes.
  • SUBJECTS AND METHODS: Data were collected about tumor size, lymph node appearance, and the results of ultrasound-guided FNA and axillary surgery of 224 patients with breast cancer undergoing 226 ultrasound-guided FNA.
  • Lymph nodes were classified as benign if the cortex was even and measured < 3 mm, indeterminate if the cortex was even but measured ≥ 3 mm or measured < 3 mm but was focally thickened, and suspicious if the cortex was focally thickened and measured ≥ 3 mm or the fatty hilum was absent.
  • The results of ultrasound-guided FNAs were analyzed by the sonographic appearance of the axillary lymph nodes and by the size of the primary tumor.
  • [MeSH-major] Axilla / pathology. Biopsy, Fine-Needle / methods. Breast Neoplasms / pathology. Lymphatic Metastasis / pathology. Ultrasonography, Interventional
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / surgery. Breast Neoplasms, Male / ultrasonography. Female. Humans. Male. Middle Aged. Neoplasm Staging. Preoperative Care. Prospective Studies. Sensitivity and Specificity. Sentinel Lymph Node Biopsy

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] AJR Am J Roentgenol. 2011 Jul;197(1):W194; author reply W195 [21700988.001]
  • (PMID = 20966338.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Xing Y, Zhao JH, Wang TS, Qiao WL, Che WJ: [The role of 18F-FDG SPECT-CT in detecting recurrence and metastases in breast cancer patients with elevated tumor markers]. Zhonghua Zhong Liu Za Zhi; 2009 Feb;31(2):129-33
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of 18F-FDG SPECT-CT in detecting recurrence and metastases in breast cancer patients with elevated tumor markers].
  • OBJECTIVE: To compare retrospectively the role of (18)F-FDG SPECT-CT and conventional imaging in the detection of recurrence and metastases in postoperative breast cancer patients with elevated level of tumor markers, and to evaluate the impact of (18)F-FDG SPECT-CT on the management of breast cancer patients.
  • METHODS: (18)F-FDG SPECT-CT was performed in 35 breast cancer patients with suspected recurrence based on elevated level of serum tumor markers.
  • The final diagnosis of recurrent breast cancer was confirmed by either pathology or observation by imaging during the follow-up for more than 1 year.
  • RESULTS: Among the 35 patients, the final diagnosis of recurrence or metastasis was established in 19 patients.
  • Of the 114 sites of increased FDG uptake, 93 were interpreted as malignant and 21 as benign.
  • CONCLUSION: In postoperative breast cancer patients with elevated level of tumor markers during the follow-up, (18)F-FDG SPECT-CT is more sensitive for detecting recurrence and metastases than conventional imaging.
  • [MeSH-major] Breast Neoplasms / pathology. Fluorodeoxyglucose F18. Lung Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Tomography, Emission-Computed, Single-Photon / methods
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Breast Neoplasms, Male / blood. Breast Neoplasms, Male / pathology. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Radiopharmaceuticals. Retrospective Studies. Whole Body Imaging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538891.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


33. Zissimopoulos A, Stellos K, Matthaios D, Petrakis G, Parmenopoulou V, Babatsikou F, Matthaiou E, Theodosiadou E, Hountis P, Koutis C: Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy. J BUON; 2009 Jul-Sep;14(3):463-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
  • PURPOSE: In this study we evaluated the clinical usefulness of serum pro-I collagen peptide (PICP) and I collagen telopeptide (ICTP) as indicators of early bone metastases in patients with breast (BC), lung (LC), urinary bladder (UBC) and prostate cancer (PC).
  • ICTP and CA 15-3 were the most reliable markers for early diagnosis of bone metastases in BC.
  • Furthermore, PICP and PSA levels were significantly higher in patients with PC and bone metastases in comparison to patients with benign prostate hyperplasia (BPH) (p <0.0001) or in patients with PC without bone metastases (p <0.0005 for PICP and p <0.0001 for PSA).
  • CONCLUSION: ICTP and CA 15-3 are the most reliable markers for early diagnosis of bone metastases in BC patients.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Collagen Type I / metabolism
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / pathology. Carcinoembryonic Antigen / metabolism. Female. Humans. Immunoradiometric Assay. Lung Neoplasms / pathology. Male. Middle Aged. Mucin-1 / metabolism. Neoplasm Metastasis. Prostate-Specific Antigen / metabolism. Prostatic Neoplasms / pathology. Sensitivity and Specificity. Tomography, Emission-Computed. Urinary Bladder Neoplasms / pathology


34. Nese N, Kandiloglu AR, Simsek G, Lekili M, Ozdamar A, Catalkaya A, Coskun T: Comparison of the desmoplastic reaction and invading ability in invasive ductal carcinoma of the breast and prostatic adenocarcinoma based on the expression of heat shock protein 47 and fascin. Anal Quant Cytol Histol; 2010 Apr;32(2):90-101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the desmoplastic reaction and invading ability in invasive ductal carcinoma of the breast and prostatic adenocarcinoma based on the expression of heat shock protein 47 and fascin.
  • RESULTS: HSP47 and fascin were localized to cytoplasm, and HSP47 and fascin IR were higher in IDC and PCa than benign groups (p < 0.05).
  • Fascin expression correlated with estrogen receptor and progesterone receptor negativity, tumor size and stage in IDC and surgical margin status in PCa.
  • Although there is no relationship with recurrence or metastatic status, fascin overexpression correlated with tumor size, which may prompt its use as a prognostic factor in IDC.

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701077.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / FSCN1 protein, human; 0 / HSP47 Heat-Shock Proteins; 0 / Microfilament Proteins
  •  go-up   go-down


35. Kisselbach C, Ristic AD, Pankuweit S, Karatolius K, Maisch B: [Women and pericardial neoplastic manifestations of the heart and pericardium]. Herz; 2005 Aug;30(5):409-15; quiz 429-30
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the proportions, most women believe that heart disease is a man's disease and that they will die of breast cancer.
  • Data on epidemiology and incidence are rare: there is only an estimated incidence of cardiac neoplasm at necropsy ranging from 0,001% to 0,3%.
  • The majority of the primary tumors are benign.
  • The most common tumor entity is benign cardiac myxoma.
  • They originate mainly from melanomas, leukemias, lymphomas, and cancer, especially of the lung or breast.
  • Indeed in women breast cancer is the most common metastatic tumor associated with pericardial effusion.
  • METHODS: A retrospective study was conducted of all patients with cardiac and pericardial neoplasm exactly diagnosed by endomyocardial or epicardial biopsy and pericardiocentesis, using hospital medical records and a biopsy and pericardiocentesis registry from 2000-2005 with 297 patients.
  • RESULTS: In 76 cases (25.6%) a neoplasm was the reason for a pericardial effusion.
  • 36 women suffered from the breast carcinoma (47%) and 40 males lung cancer (42%) as the firstly metastatic tumor.
  • By contrast, the preventive checkup and aftercare will gain more prognostic importance, especially in case of breast cancer, to earlier recognize a secondary cardiac neoplasm by biopsy and pericardiocentesis with intrapericardial treatment of neoplastic pericarditis.
  • [MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / secondary. Heart Neoplasms / epidemiology. Heart Neoplasms / secondary. Lung Neoplasms / epidemiology. Lung Neoplasms / secondary. Registries. Risk Assessment / methods
  • [MeSH-minor] Comorbidity. Female. Germany / epidemiology. Humans. Incidence. Male. Middle Aged. Retrospective Studies. Risk Factors. Sex Distribution. Sex Factors. Women's Health

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16132244.001).
  • [ISSN] 0340-9937
  • [Journal-full-title] Herz
  • [ISO-abbreviation] Herz
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


36. Rimkus C, Martini M, Friederichs J, Rosenberg R, Doll D, Siewert JR, Holzmann B, Janssen KP: Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer. Br J Cancer; 2006 Nov 20;95(10):1419-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The gene SASH1 (SAM- and SH3-domain containing 1) has originally been identified as a candidate tumour suppressor gene in breast cancer.
  • Moreover, nine benign adenomas and 10 liver metastases were analysed.
  • [MeSH-major] Colonic Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Colon / metabolism. Colon / pathology. Down-Regulation. Female. Genes, Tumor Suppressor. Humans. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Precancerous Conditions / genetics. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 2001 Jul 30;1520(1):89-93 [11470164.001]
  • [Cites] Cell Immunol. 2005 May;235(1):46-55 [16137664.001]
  • [Cites] Oncogene. 2001 Aug 30;20(38):5373-7 [11536050.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Oct 19;288(1):137-41 [11594764.001]
  • [Cites] Nat Struct Biol. 2002 Jun;9(6):453-7 [11992127.001]
  • [Cites] Oncogene. 2003 May 15;22(19):2972-83 [12771949.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Aug;37(4):369-80 [12800148.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22118-23 [15037605.001]
  • [Cites] Fam Cancer. 2004;3(2):93-100 [15340259.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):737-47 [15381729.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Nature. 1995 Feb 16;373(6515):573-80 [7531822.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27 [8996076.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(21):9646-60 [16227612.001]
  • [Cites] EMBO J. 2001 Aug 1;20(15):4173-82 [11483520.001]
  • (PMID = 17088907.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / SASH1 protein, human; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2360597
  •  go-up   go-down


37. Lardinois D, Weder W, Roudas M, von Schulthess GK, Tutic M, Moch H, Stahel RA, Steinert HC: Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer. J Clin Oncol; 2005 Oct 1;23(28):6846-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A diagnosis was obtained in 69 of these patients, including 37 (54%) with solitary metastases and 32 (46%) with lesions unrelated to the lung primary.
  • Histopathologic examinations of these 32 lesions revealed a second clinically unsuspected malignancy or a recurrence of a previous diagnosed carcinoma in six patients (19%) and a benign tumor or inflammatory lesion in 26 patients (81%).
  • The six malignancies consisted of carcinoma of the breast in two patients, and carcinoma of the orbit, esophagus, prostate, and non-Hodgkin's lymphoma in one patient each.
  • Benign tumors and inflammatory lesions included eight colon adenomas, four Warthin's tumors, one granuloma of the lower jaw, one adenoma of the thyroid gland, one compensatory muscle activity due to vocal chord palsy, two occurrences of arthritis, three occurrences of reflux esophagitis, two occurrences of pancreatitis, two occurrences of diverticulitis, one hemorrhoidal inflammation, and one rib fracture.
  • CONCLUSION: Solitary extrapulmonary FDG accumulations in patients with newly diagnosed lung cancer should be analyzed critically for correct staging and optimal therapy, given that up to half of the lesions may represent unrelated malignancies or benign disease.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Lung Neoplasms / radionuclide imaging. Neoplasm Metastasis / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Inflammation. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Radiopharmaceuticals. Sensitivity and Specificity. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16192576.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


38. Reich R, Vintman L, Nielsen S, Kaern J, Bedrossian C, Berner A, Davidson B: Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities. Diagn Cytopathol; 2005 Nov;33(5):332-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant mesothelioma (MM) is a locally aggressive and highly lethal tumor of serosal cavities that is rarely associated with clinically detectable metastasis to distant organs.
  • Effusions from patients diagnosed with ovarian (=24) and breast (=38) adenocarcinomas and MM (=24) (total = 86) were analyzed for 67-kd LR protein expression, using immunocytochemistry.
  • Protein expression of the 67-kd LR was frequently detected in carcinomas (19/24 ovarian tumors, 79%; 15/38 breast tumors, 39%), but was rare in MM (2/24 cases, 8%), despite the presence of mRNA transcripts for the receptor in all 21 specimens studied using RT-PCR.
  • Nine benign effusions that were additionally studied for protein expression were uniformly negative, as were all reactive mesothelial cells in malignant effusions.
  • Our results suggest that the 67-kd LR may aid in the differential diagnosis between metastatic carcinoma, mainly of ovarian origin, and MM.
  • They additionally suggest that the failure of MM to express the 67-kd LR protein, as opposed to the frequent expression in carcinomas with proven metastatic capacity, may be one of the factors contributing to the reduced ability of the former tumor to metastasize to distant organs.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Female. Humans. Male. Middle Aged. Molecular Weight. Neoplasm Invasiveness. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. RNA, Messenger / biosynthesis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16240397.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Laminin
  •  go-up   go-down


39. Iczkowski KA, Montironi R: Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu. J Clin Pathol; 2006 Dec;59(12):1327-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenoid cystic/basal cell carcinoma (ACBCC) is a rare neoplasm in the prostate.
  • Protein and mRNA expression were 2+ to 3+ (of 3+) in all patients with ACBCC, compared to a breast cancer control with strong reactivity, whereas protein expression was noted in only one acinar carcinoma and mRNA expression was absent in all acinar carcinomas.
  • Benign acini expressed HER-2/neu only in the basal layer.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Basal Cell / metabolism. Mixed Tumor, Malignant / metabolism. Prostatic Neoplasms / metabolism. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adult. Aged. Gene Expression. Humans. In Situ Hybridization. Male. Middle Aged. RNA, Messenger / genetics. RNA, Neoplasm / genetics


40. Waldmann J, Feldmann G, Slater EP, Langer P, Buchholz M, Ramaswamy A, Saeger W, Rothmund M, Fendrich V: Expression of the zinc-finger transcription factor Snail in adrenocortical carcinoma is associated with decreased survival. Br J Cancer; 2008 Dec 2;99(11):1900-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Snail expression was neither detected in normal adrenocortical tissue, nor in benign adrenocortical adenomas.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / metabolism. Biomarkers, Tumor / analysis. Transcription Factors / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Cadherins / biosynthesis. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Ki-67 Antigen / biosynthesis. Male. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1998 Mar 12;392(6672):190-3 [9515965.001]
  • [Cites] Horm Res. 1997;47(4-6):279-83 [9167965.001]
  • [Cites] Physiol Rev. 1959 Jan;39(1):162-82 [13623432.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):252-8 [15668718.001]
  • [Cites] Dig Dis Sci. 2005 Jan;50(1):42-6 [15712635.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1631-43 [15742334.001]
  • [Cites] Cell Cycle. 2005 Jun;4(6):772-6 [15917668.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7622-7 [16140927.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):548-58 [16098727.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):197-209 [16169465.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42 [16493418.001]
  • [Cites] Eur J Endocrinol. 2006 Apr;154(4):587-98 [16556722.001]
  • [Cites] Oncol Rep. 2006 Jul;16(1):65-71 [16786124.001]
  • [Cites] Jpn J Clin Oncol. 2006 Jun;36(6):357-63 [16766568.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5395-402 [17000672.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jan;92(1):148-54 [17062775.001]
  • [Cites] Breast Cancer Res. 2006;8(4):105 [16834762.001]
  • [Cites] Endocr Pathol. 2006 Winter;17(4):345-54 [17525483.001]
  • [Cites] Histopathology. 2007 Aug;51(2):239-45 [17593212.001]
  • [Cites] Endocr Relat Cancer. 2007 Sep;14(3):865-74 [17914115.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):711-36 [10679640.001]
  • [Cites] Mol Cell. 2001 Jun;7(6):1267-78 [11430829.001]
  • [Cites] Eur J Endocrinol. 2001 Sep;145(3):335-41 [11517015.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1113-21 [11571723.001]
  • [Cites] World J Surg. 2001 Jul;25(7):891-7 [11572030.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1613-8 [11912130.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):521-31 [12547710.001]
  • [Cites] Am J Clin Pathol. 2004 Jul;122(1):78-84 [15272533.001]
  • [Cites] Development. 2004 Sep;131(17):4213-24 [15280211.001]
  • [Cites] Nat Cell Biol. 2004 Oct;6(10):931-40 [15448698.001]
  • [Cites] Am J Clin Pathol. 1979 Sep;72(3):390-9 [474519.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):766-73 [3967172.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Endocrinology. 1990 Jun;126(6):3251-62 [2161753.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1303-9 [9137490.001]
  • [Cites] Horm Metab Res. 1998 Jun-Jul;30(6-7):421-5 [9694573.001]
  • (PMID = 19018264.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Ki-67 Antigen; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / snail family transcription factors
  • [Other-IDs] NLM/ PMC2600683
  •  go-up   go-down


41. Burke PA, Gregg JP, Bakhtiar B, Beckett LA, Denardo GL, Albrecht H, De Vere White RW, De Nardo SJ: Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules. Int J Oncol; 2006 Jul;29(1):49-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MUC1 glycoprotein that is overexpressed in aberrant forms in epithelial cancers has been used for diagnosis, staging and therapy.
  • This microarray contained 197 prostate tissue cores representing: i) normal/benign prostate;.
  • ii) prostatic intraepithelial neoplasia and Gleason grades 1 and 2; and iii) Gleason grades 3-5.
  • To further characterize the effect of glycosylation on their binding, MAb reactivities with unglycosylated MUC1 core peptide and breast and prostate cancer cell lysates were compared.
  • [MeSH-major] Antigens, Neoplasm / immunology. Biomarkers, Tumor / analysis. Epitope Mapping. Mucins / immunology. Prostatic Neoplasms / immunology
  • [MeSH-minor] Antibodies, Monoclonal / immunology. Cell Line, Tumor. Female. Glycosylation. Humans. Immunohistochemistry. Male. Mucin-1. Protein Processing, Post-Translational. Tissue Array Analysis

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16773184.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA47829
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Mucins
  •  go-up   go-down


42. Czecior E, Namysłowski G, Misiołek M, Scierski W, Polok A, Lisowska G, Mrówka-Kata K, Orecka B, Pawlas P: [Strategy of the sinonasal tumors treatment]. Otolaryngol Pol; 2007;61(4):559-61
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They state about 1% of all tumors (kidney, testum, breast, pulmonary).
  • RESULTS: In the histological examination in 4 patients the benign neoplasm and in 22 patients malignant tumors were diagnosed.
  • On the basis of the CT and MRI examination as well as the description of the surgical procedure we stated that in 13 cases the primary localization of neoplasm was the maxillary sinus, in 5 cases ethmoidal cells, in 3 nasal cavity.
  • In one patient the estimation of primary tumor localization was not possible, because of the very large extension of the neoplasm.
  • The choice of the surgical procedure was depend on the tumor extension and localization.
  • [MeSH-major] Nose Neoplasms / diagnosis. Nose Neoplasms / surgery. Paranasal Sinus Neoplasms / diagnosis. Paranasal Sinus Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260251.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


43. Granados-García M, Cortés-Flores AO, del Carmen González-Ramírez I, Cano-Valdez AM, Flores-Hernández L, Aguilar-Ponce JL: Follicular neoplasms of the thyroid: importance of clinical and cytological correlation. Cir Cir; 2010 Nov-Dec;78(6):473-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fine needle aspiration biopsy (FNAB) is useful for initial evaluation; nevertheless, malignancy is uncertain when follicular neoplasm is reported.
  • METHODS: We analyzed the clinical files of consecutive patients with cytological diagnoses of follicular neoplasm.
  • Definitive report showed 45 benign (60%) and 30 malignant (40%) cases.
  • Benign cases included 29 goiters, 11 follicular adenomas, and 5 cases of thyroiditis.
  • Malignant cases were comprised of 12 papillary carcinomas, 4 follicular carcinomas, 3 papillary carcinomas-follicular variant, 1 lymphoma, 1 teratoma, 5 medullary carcinomas, 2 insular carcinomas, 1 anaplastic carcinoma and 1 metastatic breast carcinoma.
  • Tumor size of benign lesions was 3.43 ± 2.04 cm, and 4.67 ± 2.78 (p = 0.049) for malignant lesions.
  • Age was 46.95 ± 15.39 years for benign lesions and 48.67 ± 17.28 for malignant lesions (p = 0.66).
  • [MeSH-major] Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Follicular. Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Female. Humans. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21214982.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


44. Kazakov DV, Requena L, Kutzner H, Fernandez-Figueras MT, Kacerovska D, Mentzel T, Schwabbauer P, Michal M: Morphologic diversity of syringocystadenocarcinoma papilliferum based on a clinicopathologic study of 6 cases and review of the literature. Am J Dermatopathol; 2010 Jun;32(4):340-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Syringocystadenocarcinoma papilliferum is an extremely rare cutaneous adnexal neoplasm.
  • The purpose of our investigation was to study a series of syringocystadenocarcinoma papilliferum to document morphologic variations of the neoplasm.
  • Variable present features included pagetoid migration of the neoplastic cells, dirty necrosis, mucinous ductal metaplasia, and ductal changes analogous to those seen in the breast.
  • Its association with the benign counterpart and ductal changes suggests a transformation that may involve usual ductal hyperplasia-atypical ductal hyperplasia-(ductal) adenocarcinoma in situ-invasive adenocarcinoma pathway.
  • [MeSH-minor] Adenoma, Sweat Gland / pathology. Aged. Aged, 80 and over. Carcinoma in Situ / pathology. Carcinoma, Ductal / pathology. Carcinoma, Squamous Cell / pathology. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20216201.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


45. El Sharkawy SL, Abbas NF, Badawi MA, El Shaer MA: Metallothionein isoform II expression in hyperplastic, dysplastic and neoplastic prostatic lesions. J Clin Pathol; 2006 Nov;59(11):1171-4
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: The study was carried out on formalin-fixed and paraffin-wax-embedded tissue blocks from 8 patients with benign prostatic hyperplasia, 6 patients with prostatic intraepithelial neoplasia (PIN) and 30 patients with prostatic carcinoma, using the streptavidin-biotin technique.
  • RESULTS: Patchy metallothionein staining of epithelial cells was observed in normal and benign prostatic tissues.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Metallothionein / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Intraepithelial Neoplasia / metabolism. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Disease Progression. Humans. Male. Neoplasm Proteins / metabolism. Precancerous Conditions / metabolism. Prognosis. Protein Isoforms / metabolism

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Oncol Res. 2004;10(4):207-11 [15619641.001]
  • [Cites] Cancer Detect Prev. 2001;25(1):62-75 [11270423.001]
  • [Cites] Anticancer Res. 2001 May-Jun;21(3B):1757-61 [11497256.001]
  • [Cites] Br J Nutr. 2001 Aug;86 Suppl 1:S37-53 [11520423.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] Mol Carcinog. 2002 Jan;33(1):44-55 [11807957.001]
  • [Cites] Folia Histochem Cytobiol. 2002;40(2):199-200 [12056644.001]
  • [Cites] Prostate. 2002 Jul 1;52(2):89-97 [12111700.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5325-35 [12235003.001]
  • [Cites] J Urol. 2003 Feb;169(2):721-3 [12544351.001]
  • [Cites] Cancer Lett. 2003 Oct 28;200(2):187-95 [14568174.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):2009-19 [14578200.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1388-92 [2465818.001]
  • [Cites] Tohoku J Exp Med. 1992 Jun;167(2):127-34 [1475785.001]
  • [Cites] Cancer Res. 1993 Feb 15;53(4):922-5 [8428370.001]
  • [Cites] J Urol. 1993 Aug;150(2 Pt 1):379-85 [8326560.001]
  • [Cites] Hepatology. 1993 Nov;18(5):1193-201 [8225226.001]
  • [Cites] Breast Cancer Res Treat. 1994;30(3):213-21 [7981441.001]
  • [Cites] Virchows Arch. 1994;425(5):491-7 [7850073.001]
  • [Cites] J Urol. 1996 Nov;156(5):1679-81 [8863569.001]
  • [Cites] Clin Invest Med. 1997 Dec;20(6):371-80 [9413634.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;41(1):61-8 [9443615.001]
  • [Cites] J Pathol. 1998 Feb;184(2):144-7 [9602704.001]
  • [Cites] Cancer. 1998 Sep 1;83(5):876-81 [9731889.001]
  • [Cites] Histol Histopathol. 1999 Jan;14(1):51-61 [9987650.001]
  • [Cites] J Pathol. 1999 Sep;189(1):60-5 [10451489.001]
  • [Cites] Prostate. 2000 May 1;43(2):125-35 [10754528.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2000 Mar;46(2):357-65 [10774925.001]
  • [Cites] Environ Health Perspect. 2000 May;108(5):413-8 [10811567.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2000;19(1-2):95-7 [10905514.001]
  • [Cites] Prostate. 1999 Nov 1;41(3):196-202 [10517878.001]
  • (PMID = 16574721.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Protein Isoforms; 9038-94-2 / Metallothionein
  • [Other-IDs] NLM/ PMC1860510
  •  go-up   go-down


46. Popescu I, Ciurea S, Romanescu D, Boros M: Isolated resection of the caudate lobe: indications, technique and results. Hepatogastroenterology; 2008 May-Jun;55(84):831-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: This paper reports a series of 24 isolated caudate lobe resections (ICLR), performed for 13 benign tumors (10 hemangiomas, 2 focal nodular hyperplasias, 1 adenoma) and 11 malignant tumors (3 hepatocarcinomas, 1 peripheral cholangiocarcinoma and 7 metastatic - 5 colorectal carcinomas, 1 breast carcinoma, 1 adrenal carcinoma).
  • [MeSH-minor] Adenoma, Liver Cell / mortality. Adenoma, Liver Cell / pathology. Adenoma, Liver Cell / surgery. Adrenal Gland Neoplasms / mortality. Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / surgery. Adult. Bile Duct Neoplasms / mortality. Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / surgery. Breast Neoplasms / mortality. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / mortality. Cholangiocarcinoma / pathology. Cholangiocarcinoma / surgery. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Female. Focal Nodular Hyperplasia / mortality. Focal Nodular Hyperplasia / pathology. Focal Nodular Hyperplasia / surgery. Hemangioma / mortality. Hemangioma / pathology. Hemangioma / surgery. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Postoperative Complications / etiology. Postoperative Complications / mortality. Postoperative Complications / surgery. Reoperation. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705277.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


47. Passebosc-Faure K, Li G, Lambert C, Cottier M, Gentil-Perret A, Fournel P, Pérol M, Genin C: Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions. Clin Cancer Res; 2005 Oct 1;11(19 Pt 1):6862-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions.
  • EXPERIMENTAL DESIGN: One hundred fourteen serous effusions from 71 patients with tumors and 43 patients with benign diseases were subjected to RT-PCR for expression of carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (Ep-CAM), E-cadherin, mammaglobin, mucin 1 (MUC1) isoforms MUC1/REP, MUC1/Y, and MUC1/Z, calretinin, and Wilms' tumor 1 susceptibility gene.
  • Moreover, CEA and mammaglobin were specifically expressed in epithelial malignancies, and mammaglobin was mainly expressed in effusions from breast carcinoma (97.3% of specificity).
  • CONCLUSIONS: A combination of cytology and RT-PCR analysis of CEA and Ep-CAM significantly improved the detection sensitivity of tumor cells in serous effusions.
  • RT-PCR analysis of CEA, Ep-CAM, and mammaglobin in serous effusions could be a beneficial adjunct to cytology for the diagnosis of malignancy.
  • [MeSH-major] Biomarkers, Tumor. Genetic Predisposition to Disease. Pleural Effusion, Malignant / genetics. Pleural Effusion, Malignant / metabolism
  • [MeSH-minor] Aged. Antigens / biosynthesis. Antigens, Neoplasm / biosynthesis. Ascites / metabolism. Cadherins / biosynthesis. Calbindin 2. Carcinoembryonic Antigen / biosynthesis. Carcinoma / metabolism. Cell Adhesion Molecules / biosynthesis. Cell Line, Tumor. DNA Primers / chemistry. Female. Genes, Wilms Tumor. Glycoproteins / biosynthesis. Humans. Male. Mammaglobin A. Middle Aged. Mucin-1. Mucins / biosynthesis. Neoplasm Proteins / biosynthesis. Oligonucleotides, Antisense / chemistry. Pleural Effusion. RNA / metabolism. Reverse Transcriptase Polymerase Chain Reaction. S100 Calcium Binding Protein G / biosynthesis. Sensitivity and Specificity. Uteroglobin / biosynthesis. WT1 Proteins / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203775.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Cadherins; 0 / Calbindin 2; 0 / Carcinoembryonic Antigen; 0 / Cell Adhesion Molecules; 0 / DNA Primers; 0 / EPCAM protein, human; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / Mammaglobin A; 0 / Mucin-1; 0 / Mucins; 0 / Neoplasm Proteins; 0 / Oligonucleotides, Antisense; 0 / S100 Calcium Binding Protein G; 0 / SCGB2A2 protein, human; 0 / WT1 Proteins; 63231-63-0 / RNA; 9060-09-7 / Uteroglobin
  •  go-up   go-down


48. Wegiel B, Jiborn T, Abrahamson M, Helczynski L, Otterbein L, Persson JL, Bjartell A: Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways. PLoS One; 2009;4(11):e7953
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystatin C is believed to prevent tumor progression by inhibiting the activities of a family of lysosomal cysteine proteases.
  • In the present study, we examined the expression of cystatin C and its association with matrix metalloproteinases 2 (MMP2) and androgen receptor (AR) in a tissue microarray comparing benign and malignant specimens from 448 patients who underwent radical prostatectomy for localized prostate cancer.
  • Cystatin C expression was significantly lower in cancer specimens than in benign tissues (p<0.001) and there was a statistically significant inverse correlation between expression of cystatin C and MMP2 (r(s) (2) = -0.056, p = 0.05).
  • This suggests that cystatin C may mediate tumor cell invasion by modulating the activity of MAPK/Erk cascades.
  • [MeSH-minor] Cell Line, Tumor. Disease-Free Survival. Humans. Male. Matrix Metalloproteinase 2 / metabolism. Neoplasm Invasiveness. Neoplasm Metastasis. RNA, Small Interfering / metabolism. Time Factors. Treatment Outcome


49. Stojadinovic A, Peoples GE, Libutti SK, Henry LR, Eberhardt J, Howard RS, Gur D, Elster EA, Nissan A: Development of a clinical decision model for thyroid nodules. BMC Surg; 2009;9:12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four to seven percent of the United States adult population (10-18 million people) has a palpable thyroid nodule, however the majority (>95%) of thyroid nodules are benign.
  • While, fine needle aspiration remains the most cost effective and accurate diagnostic tool for thyroid nodules in current practice, over 20% of patients undergoing FNA of a thyroid nodule have indeterminate cytology (follicular neoplasm) with associated malignancy risk prevalence of 20-30%.
  • These patients require thyroid lobectomy/isthmusectomy purely for the purpose of attaining a definitive diagnosis.
  • Given that the majority (70-80%) of these patients have benign surgical pathology, thyroidectomy in these patients is conducted principally with diagnostic intent.
  • [MeSH-major] Bayes Theorem. Decision Support Techniques. Models, Statistical. Thyroid Nodule / diagnosis. Thyroid Nodule / pathology
  • [MeSH-minor] Adult. Area Under Curve. Cohort Studies. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. ROC Curve. Thyroid Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Oct 18;92(20):1657-66 [11036111.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3686-96 [15897565.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Nov;87(11):4924-7 [12414851.001]
  • [Cites] Am Fam Physician. 2003 Feb 1;67(3):559-66 [12588078.001]
  • [Cites] Endocr Pract. 2004 May-Jun;10(3):234-41 [15310542.001]
  • [Cites] Ann Thorac Surg. 1989 Oct;48(4):556-9 [2679466.001]
  • [Cites] Clin Pharmacokinet. 1990 May;18(5):409-18 [2335046.001]
  • [Cites] Am J Med. 1992 Oct;93(4):359-62 [1415298.001]
  • [Cites] Ann Thorac Surg. 1995 Jun;59(6):1611-2 [7771861.001]
  • [Cites] Stat Med. 1995 May 15-30;14(9-10):971-86 [7569514.001]
  • [Cites] Thyroid. 1998 May;8(5):377-83 [9623727.001]
  • [Cites] Dis Colon Rectum. 2004 Dec;47(12):2015-24 [15657649.001]
  • [Cites] Ann Surg Oncol. 2005 Feb;12(2):152-60 [15827796.001]
  • [Cites] Breast Cancer. 2005;12(3):203-10 [16110290.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1792-8 [16452240.001]
  • [Cites] JAMA. 2006 May 10;295(18):2164-7 [16684987.001]
  • [Cites] AMIA Annu Symp Proc. 2005;:345-9 [16779059.001]
  • [Cites] Crit Care. 2006;10(3):R94 [16813658.001]
  • [Cites] Radiology. 2006 Sep;240(3):666-73 [16926323.001]
  • [Cites] J Natl Cancer Inst Monogr. 2006;(36):30-6 [17032892.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):239-47 [17024553.001]
  • [Cites] Anaesth Intensive Care. 2008 Jan;36(1):38-45 [18326130.001]
  • [Cites] Acad Emerg Med. 2008 May;15(5):466-75 [18439203.001]
  • [Cites] Ann Surg. 2008 May;247(5):843-53 [18438123.001]
  • [Cites] Cancer Lett. 2008 Jun 18;264(2):163-71 [18384937.001]
  • [Cites] Ren Fail. 2008;30(4):345-52 [18569905.001]
  • [Cites] Otolaryngol Head Neck Surg. 2008 Jul;139(1):21-6 [18585556.001]
  • [Cites] Phys Rev Lett. 2008 Jun 27;100(25):258701 [18643711.001]
  • [Cites] Ophthalmology. 2008 Sep;115(9):1598-607 [18342942.001]
  • [Cites] Head Neck. 2001 Apr;23(4):305-10 [11400232.001]
  • (PMID = 19664278.001).
  • [ISSN] 1471-2482
  • [Journal-full-title] BMC surgery
  • [ISO-abbreviation] BMC Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Validation Studies
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2731077
  •  go-up   go-down


50. Smith RE, Lespi P, Di Luca M, Bustos C, Marra FA, de Alaniz MJ, Marra CA: A reliable biomarker derived from plasmalogens to evaluate malignancy and metastatic capacity of human cancers. Lipids; 2008 Jan;43(1):79-89
Hazardous Substances Data Bank. 2-AMINOETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antigen tumor markers employed in monitoring therapeutical approaches are limited by their specificity (Sp) and sensitivity (Se).
  • The aim of this study was to investigate the suitability of a lipid tumor marker derived from ether-linked phospholipids and to compare it with others usually assayed in clinical practice.
  • Complex lipids from normal and pathological breast, lung, and prostate tissue were isolated and analyzed by TLC and c-GLC methods.
  • Major changes were observed in the plasmalogen sub-fraction where the ratio monoenoic/saturated fatty acids can distinguish with high Se normal tissues from either benign or neoplastic tissues from breast, lung, or prostate lesions.
  • Analyses of fatty acyl chains from ethanolamine-containing plasmalogens provided a reliable tumor marker that correlated with high Se and linearity with metastases spreading.
  • [MeSH-major] Biomarkers, Tumor / blood. Neoplasms / blood. Neoplasms / diagnosis. Plasmalogens / blood
  • [MeSH-minor] Aged. Aged, 80 and over. Ethanolamine / analysis. Female. Humans. Lipids / blood. Male. Middle Aged. Neoplasm Metastasis. Predictive Value of Tests. Prognosis. Regression Analysis. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18046593.001).
  • [ISSN] 0024-4201
  • [Journal-full-title] Lipids
  • [ISO-abbreviation] Lipids
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lipids; 0 / Plasmalogens; 5KV86114PT / Ethanolamine
  •  go-up   go-down


51. Eloubeidi MA, Cerfolio RJ, Chen VK, Desmond R, Syed S, Ojha B: Endoscopic ultrasound-guided fine needle aspiration of mediastinal lymph node in patients with suspected lung cancer after positron emission tomography and computed tomography scans. Ann Thorac Surg; 2005 Jan;79(1):263-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The reference standard included thoracotomy with complete lymphadenectomy in patients with lung cancer or if EUS-FNA was benign, repeat clinical imaging, or long-term follow-up.
  • [MeSH-major] Biopsy, Fine-Needle. Carcinoma, Non-Small-Cell Lung / secondary. Esophagoscopy. Lung Neoplasms / pathology. Lymphatic Diseases / pathology. Lymphatic Metastasis / pathology. Neoplasm Staging / methods. Positron-Emission Tomography. Tomography, X-Ray Computed. Ultrasonography, Interventional
  • [MeSH-minor] Aged. Breast Neoplasms / pathology. Carcinoma / pathology. Carcinoma / radiography. Carcinoma / radionuclide imaging. Carcinoma / secondary. Carcinoma / ultrasonography. Colonic Neoplasms / pathology. Endometrial Neoplasms / pathology. Female. Fluorodeoxyglucose F18. Granuloma / diagnosis. Histiocytosis / complications. Histiocytosis / diagnosis. Histoplasmosis / complications. Histoplasmosis / diagnosis. Humans. Kidney Neoplasms / pathology. Lung Diseases / complications. Lymphoma / pathology. Lymphoma / radiography. Lymphoma / radionuclide imaging. Lymphoma / ultrasonography. Male. Mediastinum. Middle Aged. Predictive Value of Tests. Prospective Studies. Radiopharmaceuticals. Sarcoidosis / complications. Sarcoidosis / diagnosis. Silicosis / complications. Silicosis / diagnosis. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15620955.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


52. Kurihara T, Itoi T, Sofuni A, Itokawa F, Tsuchiya T, Tsuji S, Ishii K, Ikeuchi N, Tsuchida A, Kasuya K, Kawai T, Sakai Y, Moriyasu F: Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. J Hepatobiliary Pancreat Surg; 2008;15(2):189-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result.
  • BACKGROUND/PURPOSE: It has been reported that circulating tumor cells (CTCs) can be used to predict survival in metastatic breast cancer.
  • CTC was negative in 15 patients with PC (stage II, 1; stage III, 1; stage IVa, 7; and stage IVb, 6) and in the subjects with benign conditions.
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392713.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


53. Da Ines D, Petitcolin V, Lannareix V, Montoriol P, Joubert Zakeyh J, Boyer L, Garcier J: [Liver capsule retraction adjacent to a circumscribed liver lesion: review of 26 cases with histological confirmation]. J Radiol; 2009 Sep;90(9 Pt 1):1067-74
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Rétraction capsulaire hépatique en regard d'une lésion circonscrite: à propos de 26 patients avec preuve histologique.
  • PURPOSE: To review the histological features of 26 circumscribed liver lesions associated with liver capsule retraction and discuss the differential diagnosis while evaluating for the presence of fibrous stromal reaction.
  • RESULTS: Twenty-one patients had benign or malignant liver tumors and 5 patients had confluent hepatic fibrosis.
  • Twenty of 21 liver tumors were malignant (95.2%): 3 intra-hepatic cholangiocarcinoma, 17 cases of metastatic disease including colorectal carcinoma (n=8), bronchogenic carcinoma (n=1), pancreatic carcinoma (n=4), esophageal carcinoma (n=1), breast carcinoma (n=1), gallbladder carcinoma (1) and endocrine neoplasm of the pancreas (n=1), and 1 case of liver sclerosing angioma (n=1).
  • In keeping with previous reports, metastases were frequently the cause and intrahepatic cholangiocarcinoma was the most frequent primary tumor.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Radiol. 2009 Sep;90(9 Pt 1):1019-20 [19752803.001]
  • (PMID = 19752810.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


54. Manosca F, Schinstine M, Fetsch PA, Sorbara L, Maria Wilder A, Brosky K, Erickson D, Raffeld M, Filie AC, Abati A: Diagnostic effects of prolonged storage on fresh effusion samples. Diagn Cytopathol; 2007 Jan;35(1):6-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specimens evaluated included four pleural (3 benign, 1 breast adenocarcinoma) and six peritoneal (2 ovarian adenocarcinomas, 1 malignant melanoma, 2 mesotheliomas, 1 atypical mesothelial) effusions.
  • [MeSH-major] Artifacts. Ascitic Fluid / pathology. Cytodiagnosis / methods. Neoplasms / diagnosis. Pleural Effusion, Malignant / diagnosis. Specimen Handling / methods
  • [MeSH-minor] Adult. Biomarkers, Tumor. DNA, Neoplasm / analysis. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. Time Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17173298.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


55. Jung-Hynes B, Huang W, Reiter RJ, Ahmad N: Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. J Pineal Res; 2010 Aug;49(1):60-8
Hazardous Substances Data Bank. MELATONIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prostate cancer (PCa) is a major age-related malignancy as increasing age correlates with increased risk for developing this neoplasm.
  • Additionally, employing automated quantitative analysis of a microarray containing human tissues, we found that compared to benign tissues, Clock and Per2 levels were downregulated, whereas Bmal1 levels were upregulated in PCa and other proliferative prostatic conditions.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 2005 May;91(1):47-60 [15868431.001]
  • [Cites] Carcinogenesis. 2005 Jul;26(7):1241-6 [15790588.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2827-36 [15985538.001]
  • [Cites] Cell. 2001 Dec 28;107(7):855-67 [11779462.001]
  • [Cites] Curr Top Med Chem. 2002 Feb;2(2):113-32 [11899096.001]
  • [Cites] Cell. 2002 May 3;109(3):307-20 [12015981.001]
  • [Cites] Ageing Res Rev. 2002 Jun;1(3):559-604 [12067601.001]
  • [Cites] Nature. 2002 Aug 29;418(6901):935-41 [12198538.001]
  • [Cites] Cell. 2002 Oct 4;111(1):41-50 [12372299.001]
  • [Cites] Vis Neurosci. 2002 Sep-Oct;19(5):593-601 [12507326.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):350-61 [12724733.001]
  • [Cites] Naturwissenschaften. 2003 Nov;90(11):485-94 [14610644.001]
  • [Cites] Mol Cell Endocrinol. 1991 Aug;79(1-3):C153-8 [1936532.001]
  • [Cites] J Pathol. 2005 May;206(1):111-20 [15809976.001]
  • [Cites] J Pineal Res. 2006 Jan;40(1):64-70 [16313500.001]
  • [Cites] Cancer Sci. 2006 Jul;97(7):589-96 [16827798.001]
  • [Cites] Am J Epidemiol. 2006 Sep 15;164(6):549-55 [16829554.001]
  • [Cites] Endocrinology. 2006 Oct;147(10):4618-26 [16840546.001]
  • [Cites] Cancer Lett. 2006 Nov 8;243(1):55-7 [16451817.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9789-93 [17047036.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1399-404 [17332281.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10618-22 [17975006.001]
  • [Cites] J Pineal Res. 2008 Apr;44(3):307-15 [18339126.001]
  • [Cites] Crit Rev Oncog. 2007 Dec;13(4):303-28 [18540832.001]
  • [Cites] J Pineal Res. 2008 Oct;45(3):247-57 [18341516.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3268-73 [18990770.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2008;11(4):342-8 [17984998.001]
  • [Cites] J Pineal Res. 2008 Nov;45(4):422-9 [18662218.001]
  • [Cites] Int J Biochem Cell Biol. 2009 Jan;41(1):81-6 [18817890.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3306-13 [19064543.001]
  • [Cites] Endocrinology. 2008 Nov;149(11):5527-39 [18669596.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2009 Jan;17(1):23-30 [18813126.001]
  • [Cites] FASEB J. 2009 Feb;23(2):523-33 [18945877.001]
  • [Cites] J Pineal Res. 2009 Apr;46(3):245-7 [19215573.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Jun;64(1):79-86 [18941749.001]
  • [Cites] Cancer Lett. 2009 Aug 18;281(1):1-7 [19070424.001]
  • [Cites] J Pineal Res. 2009 May;46(4):415-21 [19552765.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Pineal Res. 2009 Aug;47(1):8-14 [19522739.001]
  • [Cites] J Hypertens Suppl. 2009 Aug;27(6):S21-6 [19633447.001]
  • [Cites] FASEB J. 2009 Sep;23(9):2803-9 [19439501.001]
  • [Cites] Cancer Res. 2009 Oct 1;69(19):7619-25 [19752089.001]
  • [Cites] Cancer Res. 2009 Nov 1;69(21):8447-54 [19861541.001]
  • [Cites] Cancer Res. 2009 Dec 15;69(24):9315-22 [19934327.001]
  • (PMID = 20524973.001).
  • [ISSN] 1600-079X
  • [Journal-full-title] Journal of pineal research
  • [ISO-abbreviation] J. Pineal Res.
  • [Language] ENG
  • [Grant] United States / NCCIH NIH HHS / AT / F31 AT005393-01; United States / NCCIH NIH HHS / AT / AT005393-01; United States / NCCIH NIH HHS / AT / F31 AT005393; United States / NIEHS NIH HHS / ES / ES007015-30; United States / NIEHS NIH HHS / ES / T32ES00715-30; United States / NIEHS NIH HHS / ES / T32 ES007015-30
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ARNTL Transcription Factors; 0 / ARNTL protein, human; 0 / DBP protein, human; 0 / DNA-Binding Proteins; 0 / PER2 protein, human; 0 / Period Circadian Proteins; 0 / Transcription Factors; EC 2.3.1.48 / CLOCK Proteins; EC 2.3.1.48 / CLOCK protein, human; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; JL5DK93RCL / Melatonin
  • [Other-IDs] NLM/ NIHMS314792; NLM/ PMC3158680
  •  go-up   go-down


56. Harisinghani MG, Saksena MA, Hahn PF, King B, Kim J, Torabi MT, Weissleder R: Ferumoxtran-10-enhanced MR lymphangiography: does contrast-enhanced imaging alone suffice for accurate lymph node characterization? AJR Am J Roentgenol; 2006 Jan;186(1):144-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Seventy-seven patients (58 men, 19 women) with proven primary cancer (bladder [n = 20], breast [n = 10], endometrial [n = 1], renal [n = 3], penile [n = 4], prostate [n = 31], rectal [n = 1], testicular [n = 5], and ureteral [n = 2]) who were scheduled for surgical lymph node dissection were enrolled in the study.
  • RESULTS: Of the 169 lymph nodes evaluated, 55 were benign and 114 malignant by histopathologic analysis.
  • [MeSH-major] Contrast Media. Iron. Lymph Nodes / pathology. Lymphatic Metastasis / diagnosis. Magnetic Resonance Imaging / methods. Oxides
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dextrans. Female. Ferrosoferric Oxide. Humans. Magnetite Nanoparticles. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. ROC Curve. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Iron.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357394.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Magnetite Nanoparticles; 0 / Oxides; 0 / ferumoxtran-10; E1UOL152H7 / Iron; K3R6ZDH4DU / Dextrans; XM0M87F357 / Ferrosoferric Oxide
  •  go-up   go-down


57. Kim TY, Kim WB, Ryu JS, Gong G, Hong SJ, Shong YK: 18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope; 2005 Jun;115(6):1074-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To investigate the prevalence of incidental thyroid F-fluorodeoxyglucose (FDG) uptake in positron emission tomogram (PET) scan for evaluation in cancer patients and the role of standard uptake value (SUV) measurement in differentiation of thyroid malignancy from benign disease.
  • Cytologic diagnosis was available in 32 of 45 focal thyroid FDG uptakes.
  • In 16 (50%) patients, the tumor was found to be malignant; 14 were papillary thyroid carcinoma (surgically confirmed in 7 cases), 2 were metastatic tumor from breast and esophagus.
  • Sixteen were cytologically diagnosed as follicular cell lesions: follicular neoplasm (n = 2), nodular hyperplasia (n = 7), indeterminate follicular lesion (n = 7).
  • There was no significant difference in maximum SUV between benign and malignant nodules.
  • From 45 patients with diffuse thyroid FDG uptake, presumptive diagnosis of chronic thyroiditis was possible in 34 patients by clinical and laboratory findings.
  • CONCLUSION: Our data suggest that a cytologic diagnosis of focal thyroid FDG-PET incidentaloma regardless of SUV is mandatory considering the very high prevalence of thyroid malignancy.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Carcinoma, Papillary / pathology. Carcinoma, Papillary / radionuclide imaging. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Thyroid Nodule / radionuclide imaging. Thyroiditis

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933524.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


58. Ligr M, Li Y, Zou X, Daniels G, Melamed J, Peng Y, Wang W, Wang J, Ostrer H, Pagano M, Wang Z, Garabedian MJ, Lee P: Tumor suppressor function of androgen receptor coactivator ARA70alpha in prostate cancer. Am J Pathol; 2010 Apr;176(4):1891-900
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor suppressor function of androgen receptor coactivator ARA70alpha in prostate cancer.
  • Here we report that the full length ARA70alpha, in contrast, represses prostate cancer cell proliferation and anchorage-independent growth in vitro and inhibits tumor growth in nude mice xenograft experiments in vivo.
  • The tumor suppressor function of ARA70alpha is consistent with our previous findings that ARA70alpha expression is decreased in prostate cancer cells compared with benign prostate.
  • These results strongly suggest that ARA70alpha functions as a tumor suppressor gene.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prostate. 2003 Aug 1;56(3):192-200 [12772188.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1467-74 [12368219.001]
  • [Cites] Mol Cell Biol. 2003 Oct;23(19):7019-29 [12972618.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):1032-40 [14871982.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):13944-52 [14711828.001]
  • [Cites] Hum Mutat. 2004 Jun;23(6):527-33 [15146455.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33438-46 [15166229.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2979-85 [8187085.001]
  • [Cites] N Engl J Med. 1995 May 25;332(21):1393-8 [7723794.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 28;93(11):5517-21 [8643607.001]
  • [Cites] Prostate. 1998 Apr 1;35(1):63-70 [9537601.001]
  • [Cites] Clin Cancer Res. 1996 Feb;2(2):277-85 [9816170.001]
  • [Cites] Mol Endocrinol. 1999 Jan;13(1):117-28 [9892017.001]
  • [Cites] J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):307-13 [10419007.001]
  • [Cites] Semin Oncol. 1999 Aug;26(4):407-21 [10482183.001]
  • [Cites] Mol Endocrinol. 1999 Oct;13(10):1645-56 [10517667.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7647-54 [15520162.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Apr;42(4):342-57 [15648050.001]
  • [Cites] Mol Cancer Ther. 2005 Apr;4(4):505-15 [15827323.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5761-8 [15994951.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Aug;96(3-4):251-8 [15982869.001]
  • [Cites] Mol Endocrinol. 2005 Sep;19(9):2273-82 [15919721.001]
  • [Cites] Mol Endocrinol. 2005 Dec;19(12):2943-54 [16081517.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(5):1908-16 [16479009.001]
  • [Cites] J Cell Sci. 2006 Jul 1;119(Pt 13):2635-41 [16787944.001]
  • [Cites] Oncogene. 2006 Jun 29;25(28):3905-13 [16636679.001]
  • [Cites] J Cell Biochem. 2006 Oct 1;99(2):373-81 [16598769.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10613-20 [17079486.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):719-33 [17163421.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(7-8):1432-49 [17416541.001]
  • [Cites] Prostate. 2007 Dec 1;67(16):1801-15 [17935158.001]
  • [Cites] Am J Pathol. 2008 Jan;172(1):225-35 [18156210.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):1128-35 [18281488.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5236-41 [18356297.001]
  • [Cites] Biochim Biophys Acta. 2009 Jan;1792(1):14-26 [18992329.001]
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):132-8 [11161850.001]
  • [Cites] Mol Carcinog. 2001 Jan;30(1):1-13 [11255259.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jun;67(3):245-53 [11561770.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10226-35 [11779876.001]
  • [Cites] Cancer Metastasis Rev. 2001;20(3-4):207-23 [12085963.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):3001-15 [12089231.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2673-8 [12860943.001]
  • (PMID = 20167864.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK058024
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NCOA4 protein, human; 0 / Nuclear Receptor Coactivators; 0 / Protein Isoforms
  • [Other-IDs] NLM/ PMC2843478
  •  go-up   go-down


59. Engers R, Mueller M, Walter A, Collard JG, Willers R, Gabbert HE: Prognostic relevance of Tiam1 protein expression in prostate carcinomas. Br J Cancer; 2006 Oct 23;95(8):1081-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, Tiam1 expression was analysed in benign secretory epithelium, pre-neoplastic high-grade prostatic intraepithelium neoplasia (HG-PIN) and prostate carcinomas of 60 R0-resected radical prostatectomy specimens by semiquantitative immunohistochemistry.
  • Tiam1 proved significantly overexpressed in both HG-PIN (P<0.001) and prostate carcinomas (P<0.001) when compared to benign secretory epithelium.
  • > or =3.5-fold) in prostate carcinomas relative to the respective benign prostatic epithelium was statistically significantly associated with disease recurrence (P=0.016), the presence of lymph vessel invasion (P=0.031) and high Gleason scores (GS) (i.e.
  • Together, our data suggest that strong Tiam1 overexpression relative to the corresponding benign epithelial cells is a new and independent predictor of decreased DFS for patients with prostate cancer.
  • [MeSH-major] Guanine Nucleotide Exchange Factors / biosynthesis. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Prognosis. Prostatectomy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] J Biol Chem. 2001 Jul 27;276(30):28443-50 [11328805.001]
  • [Cites] Eur J Clin Invest. 2002 Jun;32(6):448-57 [12059991.001]
  • [Cites] Nature. 2002 Jun 20;417(6891):867-71 [12075356.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(1):21-32 [14999151.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):239-43 [15043314.001]
  • [Cites] Am J Clin Pathol. 2003 Dec;120 Suppl:S85-100 [15298146.001]
  • [Cites] NCI Monogr. 1988;(7):15-8 [3173500.001]
  • [Cites] Cell. 1994 May 20;77(4):537-49 [7999144.001]
  • [Cites] Gynecol Oncol. 1994 May;53(2):220-7 [8188083.001]
  • [Cites] Nature. 1995 Mar 30;374(6521):457-9 [7700355.001]
  • [Cites] Nature. 1995 May 25;375(6529):338-40 [7753201.001]
  • [Cites] Cell. 1995 Jun 30;81(7):1137-46 [7600581.001]
  • [Cites] J Biol Chem. 1995 Oct 13;270(41):23934-6 [7592586.001]
  • [Cites] Oncogene. 1995 Dec 7;11(11):2215-21 [8570171.001]
  • [Cites] Mol Cell Biol. 1996 Jul;16(7):3707-13 [8668187.001]
  • [Cites] Am J Surg Pathol. 1996 Mar;20(3):286-92 [8772781.001]
  • [Cites] Science. 1997 Nov 21;278(5342):1464-6 [9367959.001]
  • [Cites] Nature. 1997 Dec 11;390(6660):632-6 [9403696.001]
  • [Cites] J Cell Biol. 1998 Nov 30;143(5):1385-98 [9832565.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2005;8(2):119-26 [15809669.001]
  • [Cites] Carcinogenesis. 2006 Jan;27(1):1-22 [16195239.001]
  • [Cites] J Biol Chem. 2006 Jan 6;281(1):543-8 [16249175.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):369-76 [11054665.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):167-73 [11322835.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):41889-97 [11551917.001]
  • (PMID = 17003780.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Guanine Nucleotide Exchange Factors; 0 / TIAM1 protein, human
  • [Other-IDs] NLM/ PMC2360703
  •  go-up   go-down


60. Zhou XD, Sens MA, Garrett SH, Somji S, Park S, Gurel V, Sens DA: Enhanced expression of metallothionein isoform 3 protein in tumor heterotransplants derived from As+3- and Cd+2-transformed human urothelial cells. Toxicol Sci; 2006 Oct;93(2):322-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced expression of metallothionein isoform 3 protein in tumor heterotransplants derived from As+3- and Cd+2-transformed human urothelial cells.
  • Immunohistochemical staining of MT-3 on archival diagnostic specimens showed that only 2 of 63 (3.17%) benign bladder specimens had even weak reactivity for the MT-3 protein.
  • The gain in MT-3 expression when cells were grown as heterotransplants was also shown to occur for the MCF-7, T-47D, Hs 578t, MDA-MB-231 breast cancer, and the PC-3 prostate cancer cell lines.
  • [MeSH-minor] Animals. Biomarkers, Tumor. Breast Neoplasms / metabolism. Cells, Cultured. Female. Humans. Immunohistochemistry. Male. Mice. Neoplasm Transplantation. Prostatic Neoplasms / metabolism. Protein Isoforms. RNA, Messenger / analysis. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • Hazardous Substances Data Bank. CADMIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16854967.001).
  • [ISSN] 1096-6080
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA094997; United States / NCI NIH HHS / CA / R01 CA098832
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protein Isoforms; 0 / RNA, Messenger; 00BH33GNGH / Cadmium; 9038-94-2 / Metallothionein; N712M78A8G / Arsenic
  •  go-up   go-down


61. Kim JE, Kim HJ, Choi JM, Lee KH, Kim TY, Cho BK, Jung JY, Chung KY, Cho D, Park HJ: The antimicrobial peptide human cationic antimicrobial protein-18/cathelicidin LL-37 as a putative growth factor for malignant melanoma. Br J Dermatol; 2010 Nov;163(5):959-67
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Recent evidence suggests cathelicidin LL-37 to be a growth factor for various human cancers such as lung cancer, ovarian cancer and breast cancer.
  • Immunohistochemical analysis of melanoma, nonmelanoma skin cancer and precancerous and benign skin lesions was performed.
  • [MeSH-major] Antimicrobial Cationic Peptides / metabolism. Melanoma / metabolism. Neoplasm Proteins / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor / metabolism. Cell Movement / physiology. Cell Proliferation. Enzyme-Linked Immunosorbent Assay. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Precancerous Conditions / metabolism. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. BJD © 2010 British Association of Dermatologists.
  • (PMID = 20977442.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimicrobial Cationic Peptides; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 143108-26-3 / CAP18 lipopolysaccharide-binding protein
  •  go-up   go-down


62. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J, Kleer CG, Varambally S, Chinnaiyan AM: Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene; 2008 Dec 11;27(58):7274-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although benign epithelial cells express very low levels of EZH2, increased levels of EZH2 have been observed in aggressive solid tumors such as those of the prostate, breast and bladder.
  • The mechanism by which EZH2 mediates tumor aggressiveness is unclear.
  • Here, we demonstrate that EZH2 mediates transcriptional silencing of the tumor suppressor gene E-cadherin by trimethylation of H3 lysine 27.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 1999 Dec;23(4):474-8 [10581039.001]
  • [Cites] Oncogene. 1999 Dec 2;18(51):7274-9 [10602481.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):84-9 [10655587.001]
  • [Cites] Br J Surg. 2000 Aug;87(8):992-1005 [10931041.001]
  • [Cites] Nat Cell Biol. 2002 Mar;4(3):222-31 [11836526.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1613-8 [11912130.001]
  • [Cites] Biochim Biophys Acta. 2002 Jun 21;1602(2):151-61 [12020801.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Nature. 2002 Oct 10;419(6907):624-9 [12374981.001]
  • [Cites] Science. 2002 Nov 1;298(5595):1039-43 [12351676.001]
  • [Cites] Science. 2003 Apr 4;300(5616):131-5 [12649488.001]
  • [Cites] J Natl Cancer Inst. 2003 May 7;95(9):661-8 [12734317.001]
  • [Cites] Cancer Sci. 2003 Jul;94(7):575-81 [12841864.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11 [14500907.001]
  • [Cites] Mol Cell Biol. 2004 Jan;24(1):306-19 [14673164.001]
  • [Cites] Genes Dev. 2004 Jul 1;18(13):1592-605 [15231737.001]
  • [Cites] Am J Clin Pathol. 2004 Jul;122(1):78-84 [15272533.001]
  • [Cites] Br J Cancer. 1982 Mar;45(3):361-6 [7073932.001]
  • [Cites] Cell. 1983 Sep;34(2):455-66 [6352050.001]
  • [Cites] Surg Clin North Am. 1990 Aug;70(4):937-62 [2371651.001]
  • [Cites] J Cell Biol. 1991 Apr;113(1):173-85 [2007622.001]
  • [Cites] J Pathol. 1993 Feb;169(2):245-50 [8383197.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1690-5 [8453643.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1696-701 [8453644.001]
  • [Cites] Cancer Res. 1993 Aug 1;53(15):3618-23 [8339268.001]
  • [Cites] Am J Pathol. 1993 Dec;143(6):1731-42 [8256859.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3929-33 [7518346.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):614-6 [7880746.001]
  • [Cites] Oncogene. 1995 Oct 5;11(7):1319-26 [7478552.001]
  • [Cites] Virchows Arch. 1995;427(3):259-63 [7496594.001]
  • [Cites] Int J Cancer. 1997 Aug 22;74(4):374-7 [9291424.001]
  • [Cites] J Biol Chem. 1999 Apr 2;274(14):9656-64 [10092652.001]
  • [Cites] Semin Cell Dev Biol. 1999 Apr;10(2):227-35 [10441076.001]
  • [Cites] Biochim Biophys Acta. 1999 Oct 6;1447(1):1-16 [10500238.001]
  • [Cites] Oncogene. 2004 Nov 11;23(53):8629-38 [15467754.001]
  • [Cites] Mol Cell Biol. 2005 Jan;25(1):389-402 [15601859.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):736-43 [15720799.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1754-8 [15856046.001]
  • [Cites] World J Gastroenterol. 2005 May 28;11(20):3139-43 [15918205.001]
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):22437-44 [15817459.001]
  • [Cites] Int J Mol Med. 2005 Aug;16(2):349-53 [16012774.001]
  • [Cites] J Biol Chem. 2005 Sep 9;280(36):31470-7 [16009709.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):268-73 [16330673.001]
  • [Cites] Nature. 2006 Feb 16;439(7078):871-4 [16357870.001]
  • [Cites] Nature. 2006 Feb 16;439(7078):794-5 [16482140.001]
  • [Cites] Cell. 2006 Apr 21;125(2):301-13 [16630818.001]
  • [Cites] Genes Dev. 2006 May 1;20(9):1123-36 [16618801.001]
  • [Cites] Nature. 2006 May 18;441(7091):349-53 [16625203.001]
  • [Cites] Nat Genet. 2006 Jun;38(6):694-9 [16628213.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):846-56 [17060944.001]
  • [Cites] Genes Dev. 2006 Dec 1;20(23):3199-214 [17158740.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):232-6 [17200670.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):157-8 [17200673.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):237-42 [17211412.001]
  • [Cites] Prostate. 2007 Apr 1;67(5):547-56 [17252556.001]
  • [Cites] Genes Dev. 2007 May 1;21(9):1050-63 [17437993.001]
  • [Cites] Oncogene. 2007 Jul 5;26(31):4590-5 [17237810.001]
  • [Cites] Cancer Cell. 2007 Nov;12(5):419-31 [17996646.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10657-63 [18006806.001]
  • [Cites] Cancer Sci. 2008 Apr;99(4):738-46 [18377425.001]
  • [Cites] Nat Genet. 2008 Jun;40(6):741-50 [18488029.001]
  • (PMID = 18806826.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA129565-01A1; United States / NCI NIH HHS / CA / P50 CA069568-110020; United States / NCI NIH HHS / CA / K99 CA129565-01A1; United States / NCI NIH HHS / CA / CA111275-04; United States / NCI NIH HHS / CA / P50 CA69568; United States / NCI NIH HHS / CA / P50 CA069568-06A10016; United States / NCI NIH HHS / CA / CA069568-110020; United States / NCI NIH HHS / CA / R01 CA107469; United States / NCI NIH HHS / CA / CA069568-06A10016; United States / NCI NIH HHS / CA / K99 CA129565; United States / NCI NIH HHS / CA / U01 CA111275-04; United States / NCI NIH HHS / CA / P50 CA069568; United States / NCI NIH HHS / CA / U01 CA111275; United States / NCI NIH HHS / CA / R01 CA097063; United States / NCI NIH HHS / CA / R01 CA97063
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / DNA-Binding Proteins; 0 / Histones; 0 / Polycomb-Group Proteins; 0 / Repressor Proteins; 0 / Transcription Factors; EC 2.1.1.43 / EZH2 protein, human; EC 2.1.1.43 / Polycomb Repressive Complex 2
  • [Other-IDs] NLM/ NIHMS104449; NLM/ PMC2690514
  •  go-up   go-down


63. Paulino AC, Fowler BZ: Secondary neoplasms after radiotherapy for a childhood solid tumor. Pediatr Hematol Oncol; 2005 Mar;22(2):89-101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary neoplasms after radiotherapy for a childhood solid tumor.
  • This study was conducted to determine the outcome of patients who develop a second neoplasm after radiotherapy (RT) for a childhood solid tumor.
  • From 1956 to 1998, 429 children with a malignant solid tumor were treated at a single radiation oncology facility.
  • The medical records and radiotherapy charts were reviewed to determine if the patient developed a secondary neoplasm after treatment for malignancy.
  • Twenty-three (5.4%) patients developed a secondary neoplasm.
  • There were 14 malignant neoplasms in 13 (3.0%) and 14 benign neoplasms in 11 patients (2.6%).
  • The types of initial solid tumors treated with RT were Ewing sarcoma in 6, Wilms tumor in 6, medulloblastoma in 5, neuroblastoma in 3, and other in 3.
  • For the 14 malignant neoplasms, the median time interval from initial tumor to second malignancy was 10.1 years.
  • The 14 second malignant neoplasms (SMN) were osteosarcoma in 3, breast carcinoma in 2, melanoma in 2, malignant fibrous histiocytoma in 1, dermatofibrosarcoma in 1, leiomyosarcoma in 1, mucoepidermoid carcinoma in 1, colon cancer in 1, chronic myelogenous leukemia in 1, and basal cell carcinoma in 1.
  • The 5- and 10-year overall survival rate after diagnosis of an SMN was 69.2%; it was 70% for children with a SMN at the edge or inside the RT field and 66.7% for those outside of the RT field.
  • The 14 benign neoplasms appeared at a median time of 16.9 years and included cervical intraepithelial neoplasia in 3, osteochondroma in 3, thyroid adenoma in 1, duodenal adenoma in 1, lipoma in 1, cherry angioma in 1, uterine leiomyoma in 1, ovarian cystadenofibroma in 1, and giant cell tumor in 1.
  • Only 5 (36%) of the 14 benign tumors occurred in the RT field, with osteochondroma being the most common.
  • More than two-thirds of children with a radiation-induced malignancy are alive 10 years after the diagnosis of a SMN.
  • [MeSH-minor] Adolescent. Adult. Cause of Death. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Male. Radiation Dosage. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15804994.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


64. Chung LW, Baseman A, Assikis V, Zhau HE: Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol; 2005 Jan;173(1):10-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
  • PURPOSE: Tumor cell genotype and phenotype have been considered the only determinants supporting cancer growth and metastasis.
  • This review focuses on the published literature that suggests that tumor-microenvironment interaction has a decisive role in controlling local cancer growth, invasion and distant metastasis.
  • As this review shows, genetic alterations in prostate cancer cells alone are not enough to confer metastatic status without a supporting tumor microenvironment.
  • Effective therapeutic targeting requires a deeper understanding of the interplay between tumor and stroma.
  • Approaches co-targeting tumor and stroma already show promise over the conventional targeting of tumor cells alone in preventing prostate cancer progression and eradicating preexisting or newly developed prostate cancers in bone and visceral organs.
  • MATERIALS AND METHODS: A literature survey using the MEDLINE database was performed in basic and clinical publications relevant to tumor-host microenvironment interaction.
  • RESULTS: Tumor associated stroma actively fuel the progression of prostate cancer from localized growth to the invasion of surrounding tissues, and the development of distant bone and visceral organ metastasis.
  • In concert with this progression tumor cells recovered from metastatic sites could represent a subpopulation of preexisting tumor cells or could be a newly acquired variant subsequent to tumor-stromal interaction.
  • This presents a new opportunity for therapeutic targeting for the treatment of benign and malignant growth of the prostate glands.
  • This review summarizes specific research implicating tumor-microenvironment interaction as the molecular basis of cancer progression, providing a rationale for targeting tumor and the tumor associated microenvironment in the management of androgen independent and bone metastatic prostate cancer progression in patients.
  • Further elucidation of the molecular mechanisms underlying tumor-stromal interaction may yield improved medical treatments for prostate cancer growth and metastasis.
  • [MeSH-minor] Bone Neoplasms / physiopathology. Bone Neoplasms / secondary. Breast Neoplasms / physiopathology. Cell Differentiation. Cell Line, Tumor. Cell Transformation, Neoplastic. Disease Progression. Extracellular Matrix / physiology. Fibroblasts / physiology. Gene Expression Regulation, Neoplastic / physiology. Humans. Male. Molecular Mimicry. Neoplasm Invasiveness. Signal Transduction / physiology. Vascular Endothelial Growth Factor A / physiology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15592017.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 098912; United States / NCI NIH HHS / CA / CA 76620
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 73
  •  go-up   go-down


65. Escaff S, Fernández JM, González LO, Suárez A, González-Reyes S, González JM, Vizoso FJ: Study of matrix metalloproteinases and their inhibitors in prostate cancer. Br J Cancer; 2010 Mar 2;102(5):922-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • More than 2600 determinations on cancer specimens from 133 patients with clinically localised prostate carcinoma, 20 patients with prostatic intraepithelial neoplasia and 50 patients with benign prostate hyperplasia and controls, were performed.
  • RESULTS: When compared with benign pathologies, prostate carcinomas had higher expression of all MMPs and TIMPs.
  • [MeSH-major] Adenocarcinoma / metabolism. Matrix Metalloproteinases / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Intraepithelial Neoplasia / metabolism. Prostatic Neoplasms / metabolism. Tissue Inhibitor of Metalloproteinases / metabolism
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Follow-Up Studies. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Prognosis. Survival Rate. Tissue Array Analysis

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Dermatol. 1999 Mar;24(2):122-6 [10233668.001]
  • [Cites] J Clin Invest. 1999 May;103(9):1237-41 [10225966.001]
  • [Cites] Nat Rev Cancer. 2005 Jan;5(1):21-8 [15630412.001]
  • [Cites] Urol Res. 2005 Feb;33(1):44-50 [15517230.001]
  • [Cites] Am J Pathol. 2005 Apr;166(4):1173-86 [15793297.001]
  • [Cites] Thromb Haemost. 2005 Apr;93(4):770-8 [15841326.001]
  • [Cites] Cancer Cell. 2005 May;7(5):485-96 [15894268.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):215-27 [15947098.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2171-80 [15928670.001]
  • [Cites] J Clin Pathol. 2005 Jul;58(7):673-84 [15976331.001]
  • [Cites] Prog Urol. 2005 Apr;15(2):250-4 [15999602.001]
  • [Cites] Crit Rev Immunol. 2005;25(6):493-523 [16390324.001]
  • [Cites] Anticancer Res. 2006 Mar-Apr;26(2A):973-82 [16619495.001]
  • [Cites] Clin Exp Metastasis. 2006;23(7-8):335-44 [17136575.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):903-11 [17342087.001]
  • [Cites] Neoplasia. 2007 Apr;9(4):349-57 [17460779.001]
  • [Cites] Am J Pathol. 2007 Jun;170(6):2100-11 [17525276.001]
  • [Cites] Br J Cancer. 2007 Oct 8;97(7):957-63 [17848954.001]
  • [Cites] J Biol Chem. 2008 Mar 7;283(10):6232-40 [18174174.001]
  • [Cites] Int J Oncol. 2008 Apr;32(4):757-65 [18360703.001]
  • [Cites] Oncology. 2008;75(3-4):230-6 [18852494.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1135-49 [10694567.001]
  • [Cites] Int J Cancer. 2000 Mar 20;89(2):118-21 [10756061.001]
  • [Cites] Hum Pathol. 2000 Jul;31(7):860-5 [10923925.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4823-30 [11156241.001]
  • [Cites] J Cell Sci. 2001 Jan;114(Pt 1):111-118 [11112695.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1022-8 [11221828.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2189-93 [11280785.001]
  • [Cites] Br J Cancer. 2001 Apr 20;84(8):1076-83 [11308257.001]
  • [Cites] Neoplasia. 2001 Nov-Dec;3(6):459-68 [11774028.001]
  • [Cites] Oncogene. 2002 Mar 28;21(14):2245-52 [11948407.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Am J Clin Pathol. 2002 May;117(5):723-8 [12090420.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):657-72 [12209155.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):68-75 [12538453.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(1):15-26 [12664060.001]
  • [Cites] Int J Cancer. 2003 Nov 1;107(2):309-16 [12949813.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(3):217-22 [12970724.001]
  • [Cites] Clin Exp Metastasis. 2003;20(6):541-7 [14598888.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8511-5 [14679018.001]
  • [Cites] Breast Cancer Res. 2004;6(1):R24-30 [14680497.001]
  • [Cites] Am J Pathol. 2004 Apr;164(4):1131-9 [15039201.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1187-92 [15138554.001]
  • [Cites] Cancer Cell. 2004 May;5(5):409-10 [15144947.001]
  • [Cites] Nature. 1990 Dec 20-27;348(6303):699-704 [1701851.001]
  • [Cites] J Biol Chem. 1994 Jun 17;269(24):16766-73 [8207000.001]
  • [Cites] In Vivo. 1994 May-Jun;8(3):439-43 [7803731.001]
  • [Cites] Int J Cancer. 1996 Dec 20;69(6):448-51 [8980245.001]
  • [Cites] J Biol Chem. 1997 Mar 21;272(12):7608-16 [9065415.001]
  • [Cites] Crit Rev Oncol Hematol. 1997 May;26(1):43-53 [9246540.001]
  • [Cites] Int J Cancer. 1998 Feb 20;79(1):96-101 [9495366.001]
  • [Cites] Am J Pathol. 1998 Mar;152(3):721-8 [9502414.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] J Immunol. 1998 Dec 15;161(12):6845-52 [9862716.001]
  • [Cites] J Biol Chem. 1999 Mar 12;274(11):6935-45 [10066747.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2004;7(4):327-32 [15356679.001]
  • (PMID = 20160732.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tissue Inhibitor of Metalloproteinases; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ PMC2833257
  •  go-up   go-down


66. Milot L, Guindi M, Gallinger S, Moulton CA, Brock KK, Dawson LA, Haider MA: MR imaging correlates of intratumoral tissue types within colorectal liver metastases: a high-spatial-resolution fresh ex vivo radiologic-pathologic correlation study. Radiology; 2010 Mar;254(3):747-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In seven consecutive patients undergoing hepatic resection for liver metastases (primary colorectal in six, breast mistaken for colorectal in one), the resected fresh ex vivo liver specimen was examined with T1-weighted (repetition time msec/echo time msec, 9/4.4-4.8) and T2-weighted (2500/90) MR imaging by using a voxel size of 0.47 x 0.7 x 2 mm.
  • This SI pattern is unusual for common benign liver lesions and may be helpful in the MR imaging diagnosis of colorectal liver metastases. (c) RSNA, 2010.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. In Vitro Techniques. Linear Models. Male. Middle Aged. Neoplasm Staging. Prospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20123902.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Shukla S, Shukla M, Maclennan GT, Fu P, Gupta S: Deregulation of FOXO3A during prostate cancer progression. Int J Oncol; 2009 Jun;34(6):1613-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forkhead box transcription factor FOXO3A, an important regulator of cellular function, is thought to act as a tumor suppressor.
  • Similar findings were noted in prostate tumor specimens, in which marked cytoplasmic accumulation of FOXO3A and 14-3-3 in prostate tumors was observed with increasing Gleason grade, in contrast to exclusively nuclear accumulation in benign prostate cells.
  • These findings correlate with decreased FOXO3A DNA binding activity along with down-modulation of FOXO3A transcriptional activity with increasing tumor grade.
  • Our findings demonstrate that tumor associated alterations and redistribution of FOXO3A are frequent events in the etiology of prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):25046-51 [10837473.001]
  • [Cites] Endocr Relat Cancer. 2009 Mar;16(1):189-99 [18845647.001]
  • [Cites] Biochem Soc Trans. 2003 Feb;31(Pt 1):292-7 [12546704.001]
  • [Cites] J Cell Biol. 2004 Jan 19;164(2):175-84 [14734530.001]
  • [Cites] Cell. 2004 Apr 16;117(2):225-37 [15084260.001]
  • [Cites] Biochem J. 2004 Jun 1;380(Pt 2):297-309 [15005655.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4622-9 [14962911.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1543-56 [15509525.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4291-6 [10485474.001]
  • [Cites] Mol Cancer Res. 2005 Mar;3(3):163-9 [15798096.001]
  • [Cites] Prostate. 2005 Aug 1;64(3):224-39 [15712212.001]
  • [Cites] Cell Cycle. 2005 Jul;4(7):908-13 [15917664.001]
  • [Cites] J Biol Chem. 2005 Sep 30;280(39):33558-65 [16061480.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1062-9 [16424042.001]
  • [Cites] Endocrinology. 2006 May;147(5):2383-91 [16455781.001]
  • [Cites] Nature. 2006 May 25;441(7092):523-7 [16680151.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6998-7006 [16849544.001]
  • [Cites] Nat Cell Biol. 2006 Oct;8(10):1064-73 [16964248.001]
  • [Cites] Exp Gerontol. 2006 Oct;41(10):910-21 [16934425.001]
  • [Cites] J Biol Chem. 2007 Jan 26;282(4):2211-20 [17132628.001]
  • [Cites] Cell. 2007 Jan 26;128(2):309-23 [17254969.001]
  • [Cites] Proteins. 2007 May 1;67(2):479-89 [17256767.001]
  • [Cites] Mod Pathol. 2007 Aug;20(8):835-42 [17491598.001]
  • [Cites] Mol Endocrinol. 2007 Aug;21(8):1940-57 [17536007.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1424-32 [17551921.001]
  • [Cites] Hum Pathol. 2007 Oct;38(10):1501-7 [17597184.001]
  • [Cites] Nat Rev Cancer. 2007 Nov;7(11):847-59 [17943136.001]
  • [Cites] Oncogene. 2007 Dec 6;26(55):7647-55 [17563745.001]
  • [Cites] Nat Cell Biol. 2008 Feb;10(2):138-48 [18204439.001]
  • [Cites] Oncogene. 2008 Apr 7;27(16):2276-88 [18391970.001]
  • [Cites] Oncogene. 2008 Apr 7;27(16):2312-9 [18391973.001]
  • [Cites] Oncogene. 2008 Apr 7;27(16):2320-36 [18391974.001]
  • [Cites] Oncogene. 2008 Apr 7;27(16):2351-63 [18391977.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R21 [18312651.001]
  • [Cites] Biochem Soc Trans. 2002 Aug;30(4):391-7 [12196101.001]
  • (PMID = 19424579.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA108512-05; United States / NCI NIH HHS / CA / R01 CA108512; United States / NCI NIH HHS / CA / CA108512; United States / NCI NIH HHS / CA / R01 CA108512-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / DNA, Neoplasm; 0 / FOXO1 protein, human; 0 / FOXO3 protein, human; 0 / FOXO4 protein, human; 0 / Forkhead Transcription Factors; 0 / RNA, Messenger; 0 / Transcription Factors; EC 1.15.1.1 / Superoxide Dismutase; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ NIHMS105459; NLM/ PMC2683383
  •  go-up   go-down


68. Maruya S, Shirasaki T, Nagaki T, Kakehata S, Kurotaki H, Mizukami H, Shinkawa H: Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications. BMC Cancer; 2009;9:72
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The protein expression of topoIIalpha was evaluated immunohistochemically in formalin-fixed, paraffin-embedded tissue from 54 salivary gland carcinomas and 20 benign tumors (10 pleomorphic adenomas and 10 Warthin's tumors).
  • RESULTS: Of the 54 primary salivary gland carcinomas, 38 (70%) showed positive expression (> or = 10%) of topoIIalpha protein, and 16 carcinomas (30%) and all benign tumors were negative (p < 0.001).
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Salivary Gland Neoplasms / enzymology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / enzymology. Carcinoma, Adenoid Cystic / pathology. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 2000 Aug;22(5):489-97 [10897109.001]
  • [Cites] Head Neck. 2008 May;30(5):680-3 [17972317.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1061-7 [11948114.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1107-16 [12006526.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40 [12042765.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):235-43 [12067686.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Jan-Feb;65(1):26-32 [12624503.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):715-22 [12760291.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4682-8 [14581337.001]
  • [Cites] Int J Oncol. 2004 Jan;24(1):201-9 [14654958.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3965-70 [14666704.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):944-6 [14871971.001]
  • [Cites] J Otolaryngol. 2003 Oct;32(5):328-31 [14974865.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):637-45 [15044918.001]
  • [Cites] Arch Otolaryngol. 1984 Mar;110(3):172-6 [6322732.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):1062-9 [6088017.001]
  • [Cites] Oncology (Williston Park). 1998 May;12(5):671-80; discussion 683 [9597678.001]
  • [Cites] Pathol Res Pract. 2005;200(11-12):791-9 [15792122.001]
  • [Cites] Breast Cancer Res. 2005;7(3):R374-84 [15987433.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2673-8 [16763282.001]
  • [Cites] Cancer Treat Rev. 2007 Feb;33(1):64-77 [17113234.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):735-41 [17113340.001]
  • [Cites] Head Neck. 2007 Nov;29(11):1002-9 [17427971.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • (PMID = 19250538.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2654461
  •  go-up   go-down


69. Strobel K, Haerle SK, Stoeckli SJ, Schrank M, Soyka JD, Veit-Haibach P, Hany TF: Head and neck squamous cell carcinoma (HNSCC)--detection of synchronous primaries with (18)F-FDG-PET/CT. Eur J Nucl Med Mol Imaging; 2009 Jun;36(6):919-27
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten second cancers (18%) were located outside the aerodigestive tract (colon, five; stomach, lymphoma, breast, thymus and kidney, one each).
  • False-positive PET/CT findings were mainly related to benign FDG uptake in the intestine due to benign or precancerous polyps or physiological FDG uptake in other head and neck regions.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. False Positive Reactions. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / radiography. Neoplasms, Second Primary / radionuclide imaging. Neoplasms, Second Primary / therapy. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19205699.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


70. Hamady ZZ, Mather N, Lansdown MR, Davidson L, Maclennan KA: Surgical pathological second opinion in thyroid malignancy: impact on patients' management and prognosis. Eur J Surg Oncol; 2005 Feb;31(1):74-7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of the 66 patients reviewed, 12 (18%) had a different pathological diagnosis (kappa=0.33).
  • Two had their diagnosis changed from malignant to benign and a further two from benign to malignant.
  • Five patients had their management affected by the new pathological diagnosis.
  • [MeSH-minor] Female. Humans. Male. Neoplasm Staging. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15642429.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


71. Lincoln DT, Singal PK, Al-Banaw A: Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation. Anticancer Res; 2007 Nov-Dec;27(6B):4201-18
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 64 benign and malignant vascular tumours were obtained from different human organ sites, including the chest wall, skin, axillary contents, duodenum, female breast, abdomen, stomach, colon, lymph node, bladder, body flank and neck regions.
  • The presence of GHR in endothelial cells of vascular neoplasm indicates that they are target cells and GH is of importance in the proliferation of vascular tumour angiogenesis.
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / pharmacology. Binding Sites. Cell Growth Processes / physiology. Female. Hemangioma / blood supply. Hemangioma / metabolism. Hemangioma / pathology. Humans. Male. Mice. Mice, Inbred BALB C. Middle Aged. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. Rabbits. Rats

  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Anticancer Res. 2008 Mar-Apr;28(2b):1439
  • (PMID = 18225592.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Receptors, Somatotropin; 9002-72-6 / Growth Hormone
  •  go-up   go-down


72. Rae JM, Johnson MD, Cordero KE, Scheys JO, Larios JM, Gottardis MM, Pienta KJ, Lippman ME: GREB1 is a novel androgen-regulated gene required for prostate cancer growth. Prostate; 2006 Jun 1;66(8):886-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Gene regulated in breast cancer 1 (GREB1) is a novel estrogen-regulated gene shown to play a pivotal role in hormone-stimulated breast cancer growth.
  • RESULTS: Real-time PCR demonstrated high level GREB1 expression in benign prostatic hypertrophy (BPH), localized prostate cancer (L-PCa), and hormone refractory prostate cancer (HR-PCa).
  • [MeSH-major] Androgens / pharmacology. Cell Proliferation. Neoplasm Proteins / genetics. Neoplasm Proteins / physiology. Prostatic Neoplasms / genetics. Prostatic Neoplasms / physiopathology
  • [MeSH-minor] Cell Line, Tumor. Chromatin Immunoprecipitation. DNA, Neoplasm / drug effects. DNA, Neoplasm / genetics. Dose-Response Relationship, Drug. Estrogens / pharmacology. Gene Expression Regulation, Neoplastic / drug effects. Humans. Male. Neoplasms, Hormone-Dependent / chemistry. Neoplasms, Hormone-Dependent / genetics. Neoplasms, Hormone-Dependent / pathology. Neoplasms, Hormone-Dependent / physiopathology. Oligonucleotide Array Sequence Analysis. RNA, Messenger / analysis. RNA, Messenger / genetics. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16496412.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA069568
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / DNA, Neoplasm; 0 / Estrogens; 0 / GREB1 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering
  •  go-up   go-down


73. Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM: Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol; 2007 Mar;20(3):375-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aberrant expression of human leukocyte antigen G (HLA-G) has been proposed to be involved in tumor escape mechanisms.
  • It has been also proposed that detection of HLA-G might service as a potential biomarker for diagnosis or prediction of the clinical outcomes in ovarian and breast cancers, carcinoma of the lung and endometrial cancer.
  • In this prospectively study, HLA-G protein expression was observed in 64.6% (130/201) of the primary site colorectal carcinomas, but not in the normal colorectal tissues or benign adenomas.
  • [MeSH-major] Biomarkers, Tumor / analysis. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. HLA Antigens / biosynthesis. Histocompatibility Antigens Class I / biosynthesis
  • [MeSH-minor] Female. HLA-G Antigens. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277760.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


74. Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M: Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol; 2006 Aug;37(8):1000-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy.
  • Here we carried out an immunohistochemical survey of L1 expression in normal adults and in a broad range of benign and malignant tumors using monoclonal antibody L1-11A and the novel monoclonal antibody L1-14.10.
  • L1 was absent in breast carcinoma, gastrointestinal tract carcinomas, gastrointestinal carcinoids, renal clear-cell carcinomas, prostate adenocarcinomas, and mesotheliomas.
  • Surprisingly, L1 expression in established breast and renal carcinoma cell lines was not a predictor for its presence in these human tumors in vivo.
  • Our results suggest that L1 expression in tumors is not ubiquitous but restricted to certain subtypes and may be a helpful molecular marker for differential diagnosis and target for antibody-based therapy.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Genital Neoplasms, Female / metabolism. Isoantigens / metabolism. Membrane Glycoproteins / metabolism. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Antibodies, Monoclonal / immunology. Cell Line, Tumor. Diagnosis, Differential. Female. Fluorescent Antibody Technique, Direct. GPI-Linked Proteins. Humans. Immunoenzyme Techniques. Male. Neutrophils / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16867862.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CD177 protein, human; 0 / GPI-Linked Proteins; 0 / Isoantigens; 0 / Membrane Glycoproteins; 0 / Receptors, Cell Surface
  •  go-up   go-down


75. Leinung S, Möbius C, Udelnow A, Hauss J, Würl P: Histopathological outcome of 597 isolated soft tissue tumors suspected of soft tissue sarcoma: a single-center 12-year experience. Eur J Surg Oncol; 2007 May;33(4):508-11
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The aim of this present report was to analyze the patients referred to us with the presumptive diagnosis of soft tissue sarcoma (STS).
  • Open biopsy revealed soft tissue sarcoma in 318 cases, benign mesenchymal tumor in 124 cases and isolated metastases (ISTM) from carcinomas in 98 patients; other pathologies were found in 57 patients.
  • The primary carcinomas were lung cancer in 26 patients, breast cancer in 19 patients, renal carcinoma in 16 patients, carcinoma of the esophagus in 12 patients, colonic carcinoma in 5 patients, thyroid gland cancer in 6 patients, and in 14 patients carcinoma of unknown primary was diagnosed.
  • CONCLUSIONS: In our collective with soft tissue tumor, 50% of the patients had the diagnosis of soft tissue sarcoma, 20% presented with a metastasis of carcinoma and 20% had a benign tumor.
  • Referring to our results, in patients with the presumptive diagnosis of soft tissue sarcomas, soft tissue metastasis of a primary carcinoma was unexpectedly common, indicating that greater consideration should be given to this differential diagnosis.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17081724.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


76. He Q, Zhang P, Zou L, Li H, Wang X, Zhou S, Fornander T, Skog S: Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity. Oncol Rep; 2005 Oct;14(4):1013-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigate thymidine kinase 1 concentration in serum (S-TK1) as a potential tumor marker.
  • S-TK1 concentration and STK activity levels were determined in 9 human malignant diseases (breast, gastric, rectal, colorectal, lung, brain cancer, hepatoma, lymphoma, leukaemia) and in benign and non-cancerous diseases, representing 850 preoperative cases.
  • S-TK1 concentrations and STK activity levels in preoperative malignant patients were significantly higher than in healthy individuals, in patients with benign tumors and in those with non-cancerous diseases.
  • Significant correlations between concentration and activity level were only found in healthy individuals, in patients with benign tumors, and in some patients with malignancies, i.e. leukaemia, and breast and gastric cancers.
  • We conclude that S-TK1 concentration is a more sensitive tumor marker in solid malignancies than is STK activity.
  • [MeSH-major] Biomarkers, Tumor. Neoplasms / blood. Neoplasms / diagnosis. Thymidine Kinase / blood
  • [MeSH-minor] Breast Neoplasms / pathology. Cell Line, Tumor. Cell Proliferation. Dose-Response Relationship, Drug. Female. Humans. Male. Neoplasm Staging. Radioimmunoassay / methods. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142366.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.1.21 / Thymidine Kinase; EC 2.7.1.21 / thymidine kinase 1
  •  go-up   go-down


77. Tischler V, Fritzsche FR, Wild PJ, Stephan C, Seifert HH, Riener MO, Hermanns T, Mortezavi A, Gerhardt J, Schraml P, Jung K, Moch H, Soltermann A, Kristiansen G: Periostin is up-regulated in high grade and high stage prostate cancer. BMC Cancer; 2010;10:273
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic prostate cancers (n = 20), hormone refractory prostate cancers (n = 19) and benign prostatic tissues (n = 38) were also analyzed.
  • RESULTS: In total, strong epithelial periostin expression was detectable in 142 of 418 (34.0%) of prostate carcinomas and in 11 of 38 benign prostate glands (28.9%).
  • [MeSH-major] Biomarkers, Tumor / analysis. Cell Adhesion Molecules / analysis. Prostatic Neoplasms / chemistry
  • [MeSH-minor] Aged. Chi-Square Distribution. Cohort Studies. Epithelial Cells / chemistry. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prognosis. Prostate-Specific Antigen / analysis. Stromal Cells / chemistry. Time Factors. Up-Regulation

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biochem. 2002;86(4):792-804 [12210745.001]
  • [Cites] Mech Dev. 2001 May;103(1-2):183-8 [11335131.001]
  • [Cites] Jpn J Cancer Res. 2001 Aug;92(8):869-73 [11509119.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):843-8 [11550156.001]
  • [Cites] Cancer Lett. 2001 Oct 22;172(1):37-42 [11595127.001]
  • [Cites] J Pediatr Surg. 2002 Sep;37(9):1293-7 [12194119.001]
  • [Cites] Cell Tissue Res. 2003 Jun;312(3):345-51 [12761672.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):754-9 [12874078.001]
  • [Cites] Dev Dyn. 2004 Apr;229(4):857-68 [15042709.001]
  • [Cites] Mol Cell Biol. 2004 May;24(9):3992-4003 [15082792.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):329-39 [15093540.001]
  • [Cites] J Orthop Res. 2004 May;22(3):520-5 [15099630.001]
  • [Cites] J Appl Physiol (1985). 2004 Oct;97(4):1550-8; discussion 1549 [15121739.001]
  • [Cites] Biochem J. 1993 Aug 15;294 ( Pt 1):271-8 [8363580.001]
  • [Cites] J Bone Miner Res. 1999 Jul;14(7):1239-49 [10404027.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):77-83 [15514205.001]
  • [Cites] Anat Rec A Discov Mol Cell Evol Biol. 2005 Dec;287(2):1205-12 [16240445.001]
  • [Cites] Thyroid. 2006 Feb;16(2):161-75 [16676402.001]
  • [Cites] J Biol Chem. 2006 Jul 14;281(28):19700-8 [16702213.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6928-35 [16849536.001]
  • [Cites] Mol Cell Proteomics. 2006 Nov;5(11):2083-91 [16861259.001]
  • [Cites] Br J Cancer. 2006 Nov 20;95(10):1396-403 [17060937.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jan;101(1):83-93 [16807673.001]
  • [Cites] Oncogene. 2007 Mar 29;26(14):2082-94 [17043657.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1447-64 [17408641.001]
  • [Cites] Histol Histopathol. 2007 Oct;22(10):1167-74 [17616943.001]
  • [Cites] J Cell Physiol. 2007 Nov;213(2):374-83 [17680632.001]
  • [Cites] World J Gastroenterol. 2007 Oct 21;13(39):5261-6 [17876898.001]
  • [Cites] Int J Urol. 2007 Nov;14(11):1034-9 [17956532.001]
  • [Cites] Br J Cancer. 2008 Feb 12;98(3):604-10 [18212746.001]
  • [Cites] J Exp Med. 2008 Feb 18;205(2):295-303 [18208976.001]
  • [Cites] J Clin Pathol. 2008 Apr;61(4):494-8 [17938160.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2479-88 [18381457.001]
  • [Cites] Int J Cancer. 2008 Jun 15;122(12):2707-18 [18381746.001]
  • [Cites] Cancer. 2008 Apr 25;114(2):124-33 [18327805.001]
  • [Cites] J Endocrinol. 2008 May;197(2):401-8 [18434370.001]
  • [Cites] Stem Cells. 2008 Jun;26(6):1425-35 [18403754.001]
  • [Cites] J Histochem Cytochem. 2008 Aug;56(8):753-64 [18443362.001]
  • [Cites] Mod Pathol. 2008 Aug;21(8):1044-53 [18487994.001]
  • [Cites] Eur Urol. 2008 Nov;54(5):1097-106 [18061337.001]
  • [Cites] Clin Cancer Res. 2008 Nov 15;14(22):7430-7 [19010860.001]
  • [Cites] Prostate. 2009 Sep 15;69(13):1398-403 [19479898.001]
  • [Cites] Histopathology. 2010 Apr;56(5):600-6 [20459570.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5358-64 [12235007.001]
  • (PMID = 20534149.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / POSTN protein, human; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ PMC2903527
  •  go-up   go-down


78. Mohri Y, Mohri T, Wei W, Qi YJ, Martin A, Miki C, Kusunoki M, Ward DG, Johnson PJ: Identification of macrophage migration inhibitory factor and human neutrophil peptides 1-3 as potential biomarkers for gastric cancer. Br J Cancer; 2009 Jul 21;101(2):295-302
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI) and antibody arrays were used to compare protein expression in 21 pairs of gastric cancer tissue and adjacent normal mucosa and serum from 51 gastric cancer patients and 29 patients with benign gastric diseases.
  • Macrophage migration inhibitory factor (MIF) was increased five-fold (P=1.84 x 10(-7)) in the serum of gastric cancer patients relative to individuals with benign gastric disease.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 2001 Jan;32(1):41-4 [11154168.001]
  • [Cites] Scand J Gastroenterol. 2000 Sep;35(9):950-6 [11063155.001]
  • [Cites] Eur J Clin Invest. 2001 Apr;31(4):337-43 [11298781.001]
  • [Cites] Cancer Lett. 2001 Oct 10;171(2):125-32 [11520595.001]
  • [Cites] Tumour Biol. 2001 Sep-Oct;22(5):318-22 [11553862.001]
  • [Cites] Helicobacter. 2001 Sep;6(3):216-24 [11683924.001]
  • [Cites] Nat Immunol. 2001 Nov;2(11):1061-6 [11668338.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1449-56 [11920501.001]
  • [Cites] J Clin Pathol. 2002 Apr;55(4):298-304 [11919217.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1311-24 [11943716.001]
  • [Cites] Am J Gastroenterol. 2003 Apr;98(4):735-9 [12738449.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 2:ii31-6 [12810455.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9354-9 [12878730.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6971-83 [14583499.001]
  • [Cites] Oral Oncol. 2004 Feb;40(2):139-44 [14693236.001]
  • [Cites] Am J Clin Pathol. 2008 May;129(5):772-9 [18426738.001]
  • [Cites] J Immunol. 2008 Jun 1;180(11):7338-48 [18490733.001]
  • [Cites] Pathol Oncol Res. 2008 Mar;14(1):79-83 [18347935.001]
  • [Cites] Breast Cancer Res. 2008;10(3):R48 [18510725.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Jul;20 Suppl 2:42-7 [15335412.001]
  • [Cites] Oncology. 1999 Jul;57(1):55-62 [10394126.001]
  • [Cites] Gastric Cancer. 2004;7(4):233-9 [15616771.001]
  • [Cites] BMC Cancer. 2005 Jan 19;5:8 [15656915.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1110-8 [15709178.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):66-73 [16012935.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1485-503 [16285950.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):271-84 [16395409.001]
  • [Cites] Gut. 2006 Jun;55(6):797-802 [16488898.001]
  • [Cites] Clin Chem. 2006 Jun;52(6):1045-53 [16574760.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1898-905 [16755300.001]
  • [Cites] Immunity. 2006 Oct;25(4):595-606 [17045821.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cancer Lett. 2008 Mar 18;261(2):147-57 [18171602.001]
  • [Cites] J Exp Med. 1999 Nov 15;190(10):1375-82 [10562313.001]
  • [Cites] Am J Surg. 2001 Jan;181(1):16-9 [11248169.001]
  • (PMID = 19550422.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / Macrophage Migration-Inhibitory Factors; 0 / Neoplasm Proteins; 0 / alpha-Defensins; 0 / human neutrophil peptide 1; 0 / human neutrophil peptide 2; 0 / human neutrophil peptide 3
  • [Other-IDs] NLM/ PMC2720195
  •  go-up   go-down


79. Chang X, Han J, Pang L, Zhao Y, Yang Y, Shen Z: Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer; 2009;9:40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Expression of PADI4 was investigated in various tumors and non-tumor tissues (n = 1673) as well as in A549, SKOV3 and U937 tumor cell lines by immunohistochemistry, real-time PCR, and western blot.
  • RESULTS: Immunohistochemistry detected significant PADI4 expression in various malignancies including breast carcinomas, lung adenocarcinomas, hepatocellular carcinomas, esophageal squamous cancer cells, colorectal adenocarcinomas, renal cancer cells, ovarian adenocarcinomas, endometrial carcinomas, uterine adenocarcinomas, bladder carcinomas, chondromas, as well as other metastatic carcinomas.
  • However, PADI4 expression was not observed in benign leiomyomas of stomach, uterine myomas, endometrial hyperplasias, cervical polyps, teratomas, hydatidiform moles, trophoblastic cell hyperplasias, hyroid adenomas, hemangiomas, lymph hyperplasias, schwannomas, neurofibromas, lipomas, and cavernous hemangiomas of the liver.
  • Additionally, PADI4 expression was not detected in non-tumor tissues including cholecystitis, cervicitis and synovitis of osteoarthritis, except in certain acutely inflamed tissues such as in gastritis and appendicitis.
  • Quantitative PCR and western blot analysis showed higher PADI4 expression in gastric adenocarcinomas, lung adenocarcinomas, hepatocellular carcinomas, esophageal squamous cell cancers and breast cancers (n = 5 for each disease) than in the surrounding healthy tissues.
  • Furthermore, western blot analysis detected PADI4 expression in cultured tumor cell lines.
  • ELISA detected increased PADI4 and cAT levels in the blood of patients with various malignant tumors compared to those in patients with chronic inflammation and benign tumors.
  • Additionally, PADI4 and cAT levels were significantly associated with higher levels of known tumor markers.
  • [MeSH-major] Hydrolases / metabolism. Neoplasm Proteins / metabolism. Neoplasms / metabolism
  • [MeSH-minor] Antithrombins / metabolism. Blotting, Western. Cell Line, Tumor. Citrulline / metabolism. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Immunoprecipitation. Male. Polymerase Chain Reaction / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tumori. 1998 May-Jun;84(3):364-7 [9678618.001]
  • [Cites] Pathologe. 1996 Nov;17(6):425-32 [9082363.001]
  • [Cites] J Cell Mol Med. 2004 Oct-Dec;8(4):498-508 [15601578.001]
  • [Cites] Folia Histochem Cytobiol. 2004;42(4):235-40 [15704650.001]
  • [Cites] Rheumatology (Oxford). 2005 Mar;44(3):293-8 [15561738.001]
  • [Cites] Semin Cancer Biol. 2005 Aug;15(4):309-18 [15907383.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2936-42 [16365013.001]
  • [Cites] Mol Carcinog. 2006 Mar;45(3):183-96 [16355400.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1261-9 [16799479.001]
  • [Cites] Mol Endocrinol. 2007 Jul;21(7):1617-29 [17456793.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):76-80 [17826626.001]
  • [Cites] World J Gastroenterol. 2008 Mar 21;14(11):1682-9 [18350599.001]
  • [Cites] Histochem Cell Biol. 2008 Jun;129(6):705-33 [18461349.001]
  • [Cites] Endocr Relat Cancer. 2008 Jun;15(2):475-83 [18509000.001]
  • [Cites] J Biol Chem. 2008 Jul 18;283(29):20060-8 [18499678.001]
  • [Cites] Mol Cell Biol. 2008 Aug;28(15):4745-58 [18505818.001]
  • [Cites] Adv Exp Med Biol. 2008;630:112-32 [18637488.001]
  • [Cites] Histopathology. 2001 Jan;38(1):62-7 [11135048.001]
  • [Cites] Cell Death Differ. 2002 May;9(5):486-92 [11973607.001]
  • [Cites] Biochem Soc Trans. 2002 Apr;30(2):173-7 [12023846.001]
  • [Cites] Biochem Soc Trans. 2002 Apr;30(2):201-7 [12023851.001]
  • [Cites] Nat Genet. 2003 Aug;34(4):395-402 [12833157.001]
  • [Cites] Best Pract Res Clin Anaesthesiol. 2004 Sep;18(3):385-405 [15212335.001]
  • [Cites] Cell. 2004 Sep 3;118(5):545-53 [15339660.001]
  • [Cites] Anticancer Res. 1990 May-Jun;10(3):579-82 [2114816.001]
  • [Cites] APMIS. 1991 Nov;99(11):981-8 [1720319.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(3):209-15 [1384221.001]
  • [Cites] Int J Cancer. 1993 Jul 9;54(5):793-806 [7686887.001]
  • [Cites] Thromb Haemost. 1998 Nov;80(5):767-72 [9843169.001]
  • (PMID = 19183436.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antithrombins; 0 / Neoplasm Proteins; 29VT07BGDA / Citrulline; EC 3.- / Hydrolases; EC 3.5.3.15 / peptidylarginine deiminase type IV
  • [Other-IDs] NLM/ PMC2637889
  •  go-up   go-down


80. Xu C, Jung M, Burkhardt M, Stephan C, Schnorr D, Loening S, Jung K, Dietel M, Kristiansen G: Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy. Prostate; 2005 Feb 15;62(3):224-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Human protectin (CD59) is a regulator of complement activation that inhibits complement-mediated cell lysis, and thus might confer immune resistance to tumor cells.
  • CD59 expression has been described in a variety of human malignancies, including breast cancer.
  • The immunoreactivity of the tumor was evaluated as low versus high for statistical analysis.
  • Additionally, CD59 mRNA levels were determined by real-time PCR in matched (tumor/normal) microdissected tissues from 26 cases.
  • RESULTS: Cytoplasmic CD59 immunoreactivity was found in epithelia of prostate cancer, prostatic intraepithelial neoplasia, benign hyperplasia, atrophic, and normal glands.
  • High rates of CD59 expression were noted in 36% of prostate cancer cases and were significantly associated with tumor pT stage (P = 0.043), Gleason grade (P = 0.013) and earlier biochemical (PSA) relapse in Kaplan-Meier analysis (P = 0.0013).
  • On RNA level, we found an upregulation in 19.2% (five cases), although the general rate of CD59 transcript was significantly lower in tumor tissue (P = 0.03).
  • [MeSH-major] Adenocarcinoma / immunology. Antigens, CD59 / biosynthesis. Neoplasm Recurrence, Local / immunology. Prostate-Specific Antigen / blood. Prostatic Neoplasms / immunology
  • [MeSH-minor] Aged. Cohort Studies. Disease Progression. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Prostatectomy. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 Wiley-Liss, Inc.
  • (PMID = 15389793.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD59; 0 / RNA, Messenger; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down






Advertisement